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Background: Benzodiazepines are prescribed for anxiety and insomnia. In majority of 
cases, consumption of benzodiazepines becomes chronic and accompanies risks and 
comorbidities affecting a wide range of cognitive abilities. Cognitive behavioral therapy 
for insomnia (CBT-i) is the first line therapy for treating insomnia. Implementation of this 
therapy with benzodiazepine withdrawal programs can improve sleep quality and 
weaning success rate.  
Objective: To evaluate the effect of CBT-i on cognition upon withdrawal from a 
prolonged benzodiazepine consumption for chronic insomnia.   
Methods: 24 insomniacs aged 60 years or older, after undergoing a comprehensive 
sleep and cognitive evaluation, were randomly assigned into two groups of CBT-i (n=12) 
and waitlist (n=12). While both groups followed a structured and progressive 
benzodiazepine withdrawal program over 16 weeks, the CBT-i group additionally 
received 8 sessions of CBT-i therapy. At the end of the weaning program, both groups 
underwent the same sleep and cognitive evaluations.   
Results: All of sleep diary measures improved in the CBT-i group. Both groups showed 
improvements in insomnia severity index (p=0.000) and Pittsburgh Sleep Quality Index 
(p=0.002), while the latter improved more notably in the CBT-i group (p=0.014). 
Actigraphy, highlighted improved sleep efficiency (p=0.000) and decreased wake after 
sleep onset (p=0.008) in CBT-i group. The cognitive tests showed improvements in the 
reading speeds (time, p=0.000; score, p=0.006) and recall copying ability (p=0.040) of 




Conclusion: This study, highlight the benefits of supplementing benzodiazepine 
withdrawal with CBT-i related to improvements in sleep quality, while also sheds some 
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Definition, prevalence and risk factors of insomnia  
Primary insomnia is a prevalent sleep disorder that is not caused by medical 
conditions, psychiatric diseases, or environmental factors and is subjectively 
characterized by difficulties falling asleep (a latency of more than 30 minutes), staying 
asleep (more than 3 awakenings per night for more than 30 minutes), or having a non-
restorative sleep affecting daytime functioning, which persists over three months 
(American Psychiatric Association, 2013). 15% of adults suffer from chronic insomnia 
(Reite, Weissberg, & Ruddy, 2008) while up to 60% report experiencing one or more of 
insomnia symptoms (Ancoli-Israel & Roth, 1999; Barbar et al., 2000; Foley, Monjan, 
Simonsick, Wallace, & Blazer, 1999; Foley et al., 1995; Schubert et al., 2002; 
Woodward, 1999). According to the 3-P model proposed for insomnia (Figure 1), there 
are many risk factors contributing to development or exacerbation of insomnia which 
can be classified into three main categories: predisposing factors; precipitating factors; 
and perpetuating factors (Spielman, Caruso, & Glovinsky, 1987). The predisposing 
factors are individual traits and mainly include biological traits such as aging, female 
gender (particularly after menopausal onset) (Johnson, Roth, Schultz, & Breslau, 2006), 
family history of insomnia, psychological and personality traits including anxiety and 
depression, as well as lifestyle factors like smoking habits  (Ohayon, 2002). 
Precipitating factors, on the other hand, are external factors that contribute to insomnia 
complaints and include experiencing stressful life events (e.g., death of a close relative, 
divorce, unemployment), as well as medical or psychological complications (C.M. Morin, 




contribute to exacerbation or preservation of insomnia and include poor sleep hygiene 
and habits such as wrong beliefs about insomnia, maladaptive coping strategies for 
insomnia, or using chronic sleep medications (C.M. Morin, 1993). Although the exact 
cause of insomnia is not yet defined, it is suggested that in elderly, presence of medical 
and psychological comorbidities contribute significantly to insomnia complaints (Ford & 
Kamerow, 1989; Katz & McHorney, 1998). 
 
Pathophysiology of insomnia   
Various models have been proposed to explain development of insomnia: 
Psychiatric disorders: Forty percent of insomniacs have comorbid psychiatric 
disorders (Ford & Kamerow, 1989) among which mood and bipolar disorders, as well as 
depressive and anxiety disorders are the ones that associate most commonly with 
insomnia (Breslau, Roth, Rosenthal, & Andreski, 1996; Buysse et al., 1994; Simon & 
VonKorff, 1997). 
Medical disorders: Chronic medical conditions are commonly associated with 
poor sleep quality. Insomniacs with respiratory disorders, whether obstructive or 
restrictive lung disease, commonly experience sleep disturbances due to apnea, 
hypopnea, blood oxygen desaturation, or coughing (Weitzenblum & Chaouat, 2004). 
Cardiovascular comorbidities can contribute to disrupted sleep related to hypoxia due to 
poorer blood perfusion, orthopnea, and paroxysmal nocturnal dyspnea (Hayes, 
Anstead, Ho, & Phillips, 2009). Among other medical conditions, gastrointestinal 
diseases can cause heartburn, dyspepsia, acid brash, coughing, or choking which can 




2008; Shaker, Castell, Schoenfeld, & Spechler, 2003). Also, females, at the onset of 
menopause, report experiencing disturbances in sleep related to night sweats which 
can be explained by hormonal changes and the vasomotor instability (Ohayon, 2006).  
Normal aging: Epidemiological data suggest worsening in various sleep 
measures associated with aging. Older adults, compared with younger ones, 
experience a longer sleep latency, more fragmented sleep, longer awakenings after 
sleep onset, lower sleep efficiency and a shorter sleep duration (Dement, Miles, & 
Carskadon, 1982; Rajput & Bromley, 1999; Reynolds et al., 1985). In addition, slow 
wave sleep, which has a key role in sleep homeostasis, is decreased with age (Dement 
et al., 1982). The changes in sleep architecture of older adults could be related to 
various factors. Changes in the psychosocial aspects of elderlies’ life including 
retirement, loneliness, and isolation can directly or indirectly affect their sleep. Older 
adults are more likely to have reduced daily physical activity, which in turn by promoting 
daytime napping can decrease the drive to sleep and hence disturb the night time sleep 
(Ancoli-Israel & Ayalon, 2006). Throughout normal aging, certain biological processes 
change which can make sleeping more difficult. Elderlies experience shifts in their 
normal circadian rhythm such that they go to bed earlier and wake up too early in the 
morning (Wolkove, Elkholy, Baltzan, & Palayew, 2007). As previously discussed, 
presence of medical and psychiatric comorbidities related to aging can also lead to 
sleep complaints (Breslau et al., 1996; Buysse et al., 1994; Chen et al., 2008; Hayes et 
al., 2009; Shaker et al., 2003; Simon & VonKorff, 1997; Weitzenblum & Chaouat, 2004). 
Due to the complications and comorbidities related to aging, there is a combination of 




 Hyperarousal Model: Insomniacs, when compared to good sleepers, are thought 
to be in a state of hyperarousal, whether a physiological or a cognitive-emotional one 
(Bonnet & Arand, 2010). Physiological hyperarousal in insomniacs can be characterized 
by factors such as heart rate variability, neuroendocrine measures, sympathetic and 
parasympathetic responses, as well as functional neuroimaging. As such, insomniacs 
with physiological hyperarousal show peripheral vasoconstriction, increases in core 
body temperature, body movements, and heart rate, as well as a decrease in heart rate 
variability prior to and during sleep (Bonnet & Arand, 1998, 2003; Freedman & Sattler, 
1982; Monroe, 1967). In addition, elevated free cortisol level measured in the 
insomniacs’ urine evidences chronic stress response in this population (Vgontzas et al., 
2001; Vgontzas et al., 1998) which correlates positively with the amount of time spent 
awake after sleep onset (Vgontzas et al., 1997). A positron emission tomography study 
reported higher cerebral glucose metabolism in insomniacs during the transition from 
wake to non-rapid-eye-movement (NREM) sleep, compared to good sleepers, further 
demonstrating a hyper aroused brain in this population (Nofzinger et al., 2004). 
Cognitive-emotional hyperarousal, is characterized by increased obsessive thinking on 
life stressors combined with poor stress coping skills which can in turn impede the 
ability to go to sleep and subsequently disturb sleep quality and continuity. Development 
of insomnia in these people can lead to a shift in focus from negative thoughts about life 
stressors to worrisome thoughts about the consequences of their insomnia which can 
further deteriorate their sleep quality (Harvey, 2002). The findings of quantitative 
electroencephalography (EEG) studies are also in line with the hyperarousal model 




is followed by a decrease in high frequency brain activity (beta and gamma power) and 
an increase in slow activity (delta power) (De Gennaro, Ferrara, & Bertini, 2001), 
insomniacs show increased beta and gamma activity prior to and during the sleep as 
well as decreased delta activity throughout the NREM sleep (Lamarche & Ogilvie, 1997; 
Staner et al., 2003).  
   
Consequences of insomnia 
 Whether insomnia is developed due to physiological hyperarousal or cognitive-
emotional one, insomniacs mainly experience various comorbidities and impaired 
daytime functioning affecting a wide range of domains including cognition (attention, 
memory, concentration, decision making ability, etc.), mood (irritability, motivation, and 
energy), daytime sleepiness, accidents, personal and social relationships, occupational 
and academic performance. In other word, the quality of life in this population is notably 
reduced (American Academy of Sleep Medicine, 2014; Fortier-Brochu, Beaulieu-
Bonneau, Ivers, & Morin, 2012; Leger, Scheuermaier, Philip, Paillard, & Guilleminault, 
2001). Insomniacs, compared to good sleepers, have slower reaction times, poorer 
vigilance and attention, higher degrees of daytime sleepiness, and are 2.5 to 4.5 times 
more prone to be involved in accidents (Balter & Uhlenhuth, 1992). In regards to the 
cognitive abilities, a large longitudinal study on men above the age of 50, reported an 
association between sleep disturbances and an increased risk for dementia and 
Alzheimer’s disease (Benedict et al., 2015). Studies in younger adults have 
demonstrated that presence of insomnia symptoms among students significantly 




Egget, 2000). At work, insomniacs have poorer ability in performing more demanding 
tasks such as the ones requiring switching of attention (Shekleton et al., 2014) and also 
tend to be more frequently on sick leaves due to their insomnia (Simon & VonKorff, 
1997). In addition to the daytime functioning impairments, insomniacs experience 
medical and psychological comorbidities related to their insomnia. It is reported that 
40% of all insomniacs experience some types of psychiatric disorders – depression and 
anxiety being the most common ones, present in about 14% and 24% of the cases 
respectively (Becker, 2006). Although in the majority of cases the symptoms of 
psychiatric disorders coexist with insomnia, it is still not clear whether these are 
consequence of insomnia or a risk factor for it. This can possibly explain that a common 
physiological mechanism might exist that makes the individuals vulnerable to both 
conditions. Previous studies have consistently reported increased prevalence of medical 
conditions associated with insomnia symptoms. They highlighted that short sleep 
duration is associated with increased glucose intolerance and is shown to be a risk 
factor for development of type 2 diabetes (Gottlieb et al., 2005). Insomniacs generally 
have higher blood pressures compared to good sleepers when controlled for other 
major confounding variables. Studies have shown an association between short sleep 
duration and high risk for hypertensive diseases (Suka, Yoshida, & Sugimori, 2003; 
Vgontzas, Liao, Bixler, Chrousos, & Vela-Bueno, 2009).   
 
Treatment options for insomnia 
 Various treatment possibilities are proposed for insomnia which can be broadly 




1) Pharmacological options: Sedating antidepressants are the most prescribed 
medications for insomnia (National Institutes of Health, 2005). These hypnotics belong 
to either benzodiazepine or non-benzodiazepine family. The selection of the right option 
is influenced by several factors including symptoms and duration of insomnia, previous 
treatment experience, treatment goals, patient’s preference, cost, and the medication 
side effects.  
Benzodiazepine hypnotics are suppressants of the central nervous system acting 
through binding to both subtypes of gamma-aminobutyric acid (GABA) type A receptors 
(GABA-Benzodiazepine-1 and GABA-Benzodiazepine-2) which are ligand-gated 
chloride-selective ion channel in the central nervous system (Lieberman, 2007). Binding 
of the specific ligands and activation of GABA receptors leads to opening of the chloride 
channels, influx of chloride ions into the neuron, and hyperpolarization of the neuron. 
Because of the wide distribution of GABA receptors in the nervous system, GABA plays 
a role in various functions including regulating anxiety, pain, release of sex hormones, 
blood pressure, blood sugar, and etc. It is suggested that GABA also contributes to 
regulating memory and sleep. For instance, GABA-Benzodiazepine-1 is shown to 
regulate wake-sleep cycle and promote drowsiness while GABA-Benzodiazepine-2 is 
involved in regulating memory, cognitive performance, and psychomotor functioning 
(Wamsley & Hunt, 1991). A theory supporting the involvement of benzodiazepines in 
promoting sleep suggests that these ligands bind non-specifically to the two subtypes of 
GABA-A receptors and promote relaxation and drowsiness (Nutt, 2006), which can in 
turn treat problems related to the onset and maintenance of the sleep. Although 




and also increase the total sleep time, they alter the sleep architecture. At the macro 
level, these hypnotics increase the proportion of sleep spent in stages N1 and N2 of 
NREM sleep, while suppressing the deep sleep (stage N3 of NREM sleep) and REM 
sleep (Greenblatt, 1991). At the micro level, chronic consumers of benzodiazepines 
show increased sleep spindles, higher brain activity in theta, sigma, and beta 
frequencies, and decreased slow wave activity. Benzodiazepines, like any other 
medication, are not free of side effects and their chronic use can lead to complications 
including impairments in psychomotor and cognitive performance, and anterograde 
amnesia (Ashton, 1994; Vgontzas, Kales, & Bixler, 1995). In long term, these 
medications can lead to development of tolerance, which in turn demands an increase 
in the medication dose to remain effective. This vicious cycle is usually followed by 
physiological and psychological dependence (Colbert, 2008; Vgontzas et al., 1995).  
Non-benzodiazepines act similarly to benzodiazepines, except that unlike 
benzodiazepines, they selectively bind to GABA-Benzodiazepine-1 receptors, and 
promote drowsiness and sleep. Non-benzodiazepines, compared to sedatives in 
benzodiazepine family, are accompanied by less severe side effects (in cognitive and 
psychomotor performance), tolerance, and dependence, which could be explained by 
their low affinity towards binding to GABA-Benzodiazepine-2 receptors (Berlin et al., 
1993; Mintzer, Frey, Yingling, & Griffiths, 1997; Wesensten, Balkin, & Belenky, 1996) 
and their shorter half-life.  
Melatonin agonists: Melatonin is a hormone secreted by the pineal gland during 
the night, which binds to the melatonin receptors located in the suprachiasmatic nucleus 




agonists such as Ramelteon has been associated with a decrease in subjective sleep 
latency and an increase in total sleep time (Kuriyama, Honda, & Hayashino, 2014; Roth 
et al., 2006). Since this medication decreases the sleep latency, it is more effective in 
treating sleep onset insomnia, rather than problems related to the sleep maintenance. 
Melatonin agonists, unlike benzodiazepines, accompany milder side effects (Schutte-
Rodin, Broch, Buysse, Dorsey, & Sateia, 2008) and have smaller potentials to cause 
dependence. Although Melatonin agonists show promising improvements in sleep 
measures and are shown to be safer, the effect sizes for the data are relatively small.  
Orexin receptor antagonists:  Orexin – also known as hypocretin – is a 
hypothalamic neuropeptide that regulates sleep-wakefulness cycles. Two subtypes of 
hypocretins, Orexin A and B, play a key role in promoting wakefulness and regulating 
the sleep-wake cycle (Mieda & Sakurai, 2012). Limited number of studies have 
suggested potential effect of orexin receptor antagonist on improvements of insomnia. It 
has been proposed that Orexin receptor antagonists, by binding to orexin receptors, can 
inhibit the wakefulness promoting effect of orexins and hence help with natural transition 
from wakefulness into sleep (Colbert, 2008). Clinical trial studies have reported these 
medications as safe drugs with low level of physical dependence and withdrawal 
symptoms.  
 
2) Non-pharmacological options: In addition to the pharmacological therapy 
option, there are psychological and behavioral techniques that can help treat insomnia, 
among which cognitive behavioral therapy for insomnia (CBT-i) is the most effective one 




has minimal adverse effects (C. M. Morin et al., 2006). For this reason, many 
governmental bodies, including the National Institute of Health Consensus Statement 
(National Institutes of Health, 2005), American College of Physicians (Qaseem et al., 
2016), and British Association of Psychopharmacology (Wilson et al., 2010) recommend 
CBT-i as the first line of treatment for insomnia. CBT-i is a structured therapy program, 
offered individually or in groups, that combines various psychological and behavioral 
components that aim to improve sleep habits and behaviors. These components include 
cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation 
which are further detailed bellow: 
Cognitive therapy aims to identify and correct dysfunctional beliefs and 
misconceptions about sleep and insomnia, including wrong impressions about minimum 
daily sleep requirements, fears about losing sleep, or over-estimating the consequences 
of insomnia. Negative thoughts about insomnia prior to sleep could trigger the 
autonomic arousal system and hence negatively affect sleep quality and integrity 
(Harvey, 2002; Harvey, Sharpley, Ree, Stinson, & Clark, 2007; C. M. Morin et al., 2006). 
Stimulus control aims to educate the patients to associate the bed only with 
sleeping and not with any other activity whether stimulating or not (C. M. Morin et al., 
2006). These instructions include but not limited to, going to bed only when sleepy, not 
spending more than 20 minutes in bed awake, leave the bed if cannot fall asleep within 
this 20-minute time frame, and only return when sleepy again.  
Sleep restriction component, as the name suggests, instructs the patients to limit 
their sleep and the time in bed (C. M. Morin et al., 2006; Spielman, Saskin, & Thorpy, 




complaints, sleep restriction increases the sleep pressure and the homeostatic drive to 
sleep and hence improves the sleep efficiency.  
 Sleep hygiene educates the patients about the environmental, physiological, 
behavioral, and habitual factors that promote a well-integrated sleep (C. M. Morin et al., 
2006). The list includes but is not limited to avoiding daytime naps, restricting alcohol, 
caffeine, and nicotine intake, dietary advices, and instructions on how to keep the 
bedroom environment optimal for sleeping. 
Relaxation consists of a collection of techniques that can be used based on the 
patient’s personal choice, including meditation, mindfulness, progressive muscle 
relaxation, guided imagery, and breathing techniques (C. M. Morin et al., 2006). The 
purpose of this component is to reduce the cognitive arousal and muscle tensions, and 
promote sleep.  
While medications need to be continuously consumed in order to remain 
effective, CBT-i helps insomniacs to develop skills, which can be applied even after the 
termination of the intervention. In fact, this might explain why CBT-i shows a better 
efficacy in treating insomnia in the long term, compared to pharmacotherapeutic 
options. One study, evaluating the effect of non-pharmacological sleep therapy on brain 
functional activity in a small sample of chronic insomniacs (n=21), reported 
hypoactivation of prefrontal cortex in chronic insomniacs (compared to controls) which 
recovered upon receiving a six week non-pharmacological sleep therapy consisting of 
CBT-i, body temperature and bright light interventions, and physical activity counseling 




function, CBT-I therapy complementing the benzodiazepine withdrawal could potentially 
help improve this domain.  
 
Chronic use of benzodiazepines in Elderly 
Benzodiazepines are prescribed extensively to elderly mainly for anxiety and 
insomnia complaints. In Canada, about 25% of adults over the age of 65 consume 
benzodiazepines (Hogan et al., 2003). Although the recommended treatment duration is 
usually between two to four weeks, in majority of cases this consumption becomes 
chronic either due to the dependency developed during the four weeks of consumption, 
or over-prescriptions by doctors. Accordingly, in Quebec, 20% of the elderly population 
take benzodiazepines in the long course (Egan, Moride, Wolfson, & Monette, 2000). 
This prolonged use is not free of risks. Many studies have demonstrated associations 
between chronic consumption of benzodiazepines and the occurrence of comorbidities 
in elderly. In particular, the chronic use of benzodiazepines is shown to be a risk factor 
for the cognitive decline, which can affect a wide range of cognitive functions such as 
memory, attention, concentration, and psychomotor performance (Barker, Greenwood, 
Jackson, & Crowe, 2004a; Golombok, Moodley, & Lader, 1988). A 15-year longitudinal 
study on 253 dementia patients revealed that the use of benzodiazepines increases the 
risk of development of dementia by 50% (Billioti de Gage et al., 2012). Chronic use of 
benzodiazepines does not only affect the mental and cognitive performance, but also 
the physical abilities. Older adults with chronic benzodiazepine consumption are at 
greater risks of mobility incidences and disabilities related to activities of daily living (i.e., 




people are also at higher risks for falls and experiencing hip fractures (Cumming & Le 
Couteur, 2003; Ray, Griffin, Schaffner, Baugh, & Melton, 1987; Tom, Wickwire, Park, & 
Albrecht, 2016). The excessive use of benzodiazepines has a direct negative impact on 
the cognitive and physical well-being of the elderly population.  
 
Benzodiazepines withdrawal in elderly 
Given the detrimental effects of chronic benzodiazepine consumption on 
cognition and physical abilities, several studies have investigated whether these deficits 
would remain after weaning from these hypnotics. The result of these studies show that 
cessation of treatment with benzodiazepines improves all cognitive domains affected, 
notably improving attention, concentration, psychomotor speed, problem solving 
abilities, and visuospatial skills with a medium effect size or larger (d>0.5) (Barker, 
Greenwood, Jackson, & Crowe, 2004b). However, this recovery is not complete and the 
weaned patient would retain some residual deficits in most cognitive functions as 
compared to individuals who have never used these drugs (Barker et al., 2004b; Barker, 
Greenwood, Jackson, & Crowe, 2005). The persistence of these deficits could be 
explained by the maintenance or worsening of sleep disturbances secondary to 
weaning.  
Although studies support the notion that withdrawal from benzodiazepines can 
help improve, even though partially, the affected cognitive and physical domains, there 
are limitations to this strategy. Primarily, the weaning success rate in chronic 
benzodiazepine users is not optimal. A randomized control trial evaluating the weaning 




only 48% of patients completely succeeded in becoming medication free (C. M. Morin et 
al., 2004). Withdrawal from benzodiazepines does not target correcting for the 
underlying problem that caused taking these medications in the first place. This is 
indeed important since an individual who had been taking benzodiazepines for sleep 
problems, would most likely experience the same troubles after weaning, if their 
insomnia is not treated during the weaning period.   
 
Combination of CBT-i and benzodiazepine withdrawal  
 Given the limitations that weaning from benzodiazepines accompany (low 
weaning success rate, persistence of residual deficits, and rebound of the underlying 
condition), and the high efficacy of CBT-i in treating chronic insomnia, recent studies 
have investigated the efficacy of a combination therapy consisting of CBT-i and a 
structured weaning intervention. The results show that implementation of CBT-i can 
achieve a complete cessation of benzodiazepine use in 85% of elderly patients as 
opposed to 48% in case of withdrawal without CBT-I (C. M. Morin et al., 2004). Also, 
improvements in sleep quality related to benzodiazepines are not maintained in long 
term and sleep indices gradually return to the baseline values within a year (C. M. 
Morin, Colecchi, Stone, Sood, & Brink, 1999). However, combination of CBT-i and 
weaning intervention lead to improvements in sleep parameters which are maintained 
even one year after the intervention. Thus, not only these data represent CBT-i as the 
treatment of the choice for insomnia, they further highlight the key role of this 
psychotherapy in helping weaning from benzodiazepines.  




Even though the existing studies have shown that CBT-i improves the weaning 
success rate as well as the sleep quality in older adults (C. M. Morin et al., 2004; C. M. 
Morin et al., 1999), the effect of CBT-i on improving cognitive performance in elderly 
population is understudied.  
Since CBT-i allows weaning with higher success rates among a greater 
proportion of patients (C. M. Morin et al., 2004) and this withdrawal is accompanied by a 
cognitive improvement (Barker et al., 2004b), even though partial, we expect that this 
psychological intervention leads to an improved cognitive recovery. 
The research objectives: 
Over the course of my Master’s degree, we intended to evaluate the effect of 
CBT-i on sleep and cognition in elderly population upon withdrawal from a prolonged 
benzodiazepines consumption prescribed for chronic primary insomnia. We proposed to 
conduct a prospective randomized controlled study evaluating the sleep measures and 
neuropsychological performance before and after the withdrawal response, among a 
group of elderly who were randomly assigned into two groups, one initially receiving a 
cessation intervention only (waitlist group), and the other, a combined CBT-i and 
cessation intervention (CBT-i group). The objectives of the study were to evaluate the 
potential benefits of CBT-i on improving sleep and cognitive performance secondary to 
benzodiazepine withdrawal among an elderly population.  
The research hypotheses:  
 Given the potential benefits of CBT-i on improving the sleep quality and weaning 




1) Upon weaning, the sleep quality, more particularly the subjective sleep 
measures, will improve in CBT-i group compared to the controls (waitlist group) 
2) While both groups will show improved cognitive performance as a result of 
benzodiazepine withdrawal, this improvement is more pronounced in the CBT-i 




Material and methods  
A schematic of the study design is presented in Figure 2.  
Participants  
Participants were recruited via various methods, but mainly through outpatient 
clinics of Institut Universitaire de Gériatrie de Montréal (IUGM) where Dr. Dang-Vu is a 
consultant neurologist specialized in sleep disorders and researcher. Information sheets 
regarding the inclusion and exclusion criteria of the study were distributed to the doctors 
and staff and the information of the potential patients were entered in the IUGM 
participants’ database. Patients were also recruited through local posters that were 
displayed at the research center of IUGM as well as a series of external pharmacies 
that previously participated in similar studies of benzodiazepine withdrawal. In addition, 
a few participants were recruited through a series of interviews with different 
newspapers/journals (e.g., Metro, Le Bel Age) as well as radio-television channels (e.g., 
Radio Canada). 
Inclusion criteria: patients with the following criteria were deemed eligible: 
1) 60 years of age or more  
2) Having used benzodiazepines for chronic insomnia at more than 50% of 
the nights for the past 3 months. 
Exclusion criteria: the patients should have not had any of the following:  
1) Pronounced cognitive deficits (MMSE score less than or equal to 23/30);  
2) Dementia;  




4) Severe sensory or motor impairments;  
5) History of epilepsy; 
6) Current uncontrolled major depression defined by a clinical diagnosis for 
which no medication is being taken;  
7) Psychotic disorders or current consumption of antipsychotic medications;  
8) History of alcoholism or drug abuse;  
9) Moderate to severe sleep apnea (more than 15 apnea and/or hypopnea 
events per hour); 
10) Palliative care; 
11) Insufficient knowledge of French language (since the CBT-i sessions are 
offered in French, and neurocognitive tests should be made in the same 
language across participants, to allow comparisons between subjects). 
After an initial phone screening according to the above-mentioned 
inclusion/exclusion criteria, potentially eligible participants were personally interviewed, 
using semi-structured questionnaires, by a psychologist for further evaluating their 
general eligibility as well as a psychiatrist for assessing the psychiatric exclusion 
criteria. The ones who passed these screenings, after agreeing to continue participating 
in the study and signing the informed consent form, underwent a polysomnography 
(PSG) sleep recording using the SOMNO-screen device (SOMNOmedics, 
Randersacker, Germany) in the sleep lab located at the research center of IUGM. The 
PSG montage consisted of EEG and electrooculography (EOG) referenced to linked 
mastoids, as well as recordings of nasal/oral airflow, submental bipolar and bilateral 




well as thoracic and abdominal effort. This first in-lab PSG night was used to evaluate 
and rule out the presence of any possible sleep disorders besides insomnia, such as 
moderate to severe sleep apnea (index>15 events/hour) as they served as exclusion 
criteria. Additionally, this PSG recording acted as a habituation night, to minimize the 
effects of the new environment and the discomforts due to the PSG equipment on the 
quality of the sleep. 
 
Sleep evaluations at the baseline 
The participants who were still eligible after the PSG screening then underwent a 
comprehensive objective and subjective sleep evaluation. The objective sleep 
evaluations included a second night of in-lab PSG recording, as well as actigraphy 
recording using a wrist worn accelerometer (Actiwatch, Respironics, Pittsburgh, PA) that 
monitors sleep pattern by recording a combination of intensity, amount and duration of 
the wrist movement and light intensity.  
The PSG recording was done at the research center of IUGM using a 33 channel 
SOMNO-screen device. The participants were given information about the PSG well in 
advance, and were asked to refrain drinking alcoholic and caffeinated drinks and also 
avoid intense physical activity for at least 8 hours prior to the PSG recording. On the 
day of the recording, subjects arrived to the sleep lab about two hours prior to their 
normal sleeping time to allow ample time for installation of the electrodes. The montage 
consisted of EEG and EOG referenced to linked mastoids as well as recordings of 
submental bipolar electromyography and electrocardiography. Participants went to bed 




scored in 30-second epochs according to the American Academy of Sleep Medicine 
(AASM) scoring criteria (Iber, 2007). The PSG analyses allows characterization of the 
sleep microarchitecture and calculation of certain sleep parameters such as the latency 
to the sleep onset, total sleep time, duration of wakefulness after the sleep onset, as 
well as sleep efficiency and sustained sleep efficiency. Latency to the sleep onset, also 
known as sleep latency, is defined as the time it takes from the point that the individual 
tries to go to sleep until the sleep onset. Total sleep time is the duration from the sleep 
onset until the time the individual wakes up in the morning minus the total duration of 
the awakenings throughout the night. Sleep efficiency, reported in percentage, is 
calculated based on the ratio of the total sleep time to the time spent in bed while 
sustained sleep efficiency is total sleep time over time spend in bed after the sleep 
onset. 
Since there is a large night to night variability in the sleep pattern and 
architecture of the insomniacs, and due to our limitation in having participants 
undergoing in-lab PSG recordings for multiple times, we also used actigraphy in order to 
evaluate the sleep pattern of the insomniacs over a 14-day period. Actigraphy is a 
method of monitoring the sleep pattern that uses a wrist-worn accelerometer which 
objectively evaluates the sleep patterns including sleep latency, duration, efficiency and 
wake after sleep onset based on the level of the lighting and participants’ wrist activity 
through a validated automatic algorithm which was further validated based on 
participants self-reported daily bed and wake times.  
In addition to the objective sleep measures, we evaluated the sleep quality using 




Epworth Sleepiness Scale), as well as self-reported sleep diaries completed over the 
period of 14 days.  
Insomnia severity index (ISI) (Bastien, Vallieres, & Morin, 2001) is a self-reported 
7-item questionnaire, with a 5-point Likert scale (range: 0-4) for each item. ISI measures 
the nature, severity, and impact of insomnia over the past month by evaluating the 
problems related to sleep onset, sleep maintenance, and early morning awakenings, 
sleep dissatisfaction, association between sleep problems and daytime functioning, 
noticeability of sleep problems by others, and distress caused by the sleep difficulties. 
The total score for this questionnaire ranges from zero to 28, with the scores of 0-7 
characterizing absence of insomnia; 8-14 sub-threshold; 15-21 moderate; and 22-28 
severe insomnia.   
Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, Monk, Berman, & 
Kupfer, 1989), unlike ISI, does not specifically target insomniacs and can be applied to 
study the pattern and disturbances of sleep in the general population. This 
questionnaire consists of 7 components, each with a 4-point Likert scale (range: 0-3), 
yielding in a total score between 0-21. A total PSQI score of 5 or greater suggests poor 
sleep quality.  
Epworth sleepiness scale (ESS) (Johns, 1991) is an 8-item self-administered 
questionnaire that assesses the daytime somnolence by evaluating the probability of 
dosing-off in eight different common life situations. ESS uses a 4-point Likert format 
ranging from 0-3, and yields in a total score between 0-24.  
The participants were also given sleep diaries (Carney et al., 2012), in order to 




their sleep latency, duration, efficiency, as well as the wake after sleep onset averaged 
over a 14 day period.  
Given the strong association between mood disorders with insomnia, we 
additionally assessed the anxiety and depression states of the participants using 
Geriatric Anxiety Inventory (GAI) (Pachana et al., 2007), a 20 item self-reported 
questionnaire that evaluates the anxiety levels over the past seven days as well as 
Geriatric Depression Scale (GDS) (Yesavage et al., 1982), a 30 item questionnaire 
identifying the depression symptoms over the past week.   
 
Neuropsychological evaluations at the baseline  
 The morning after the second PSG night, participants met with a 
neuropsychologist and underwent a comprehensive neuropsychological examination in 
order to evaluate their cognitive performance before weaning from benzodiazepines. 
The rationale for performing these tests after the second PSG night, as opposed to the 
first night, was to ensure that all those tested were eligible according to our inclusion 
criteria and were not excluded due to sleep disorders detected by PSG. In addition, the 
second PSG night was closer to the start of the CBT-i therapy; as such, we thought that 
the scores obtained the morning after would be a better representative for the baseline 
values. Various neuropsychological tests were administered to assess performance in 
specific cognitive domains which have shown to improve more prominently upon 
benzodiazepine withdrawal including verbal memory, executive function, attention and 




summary of these tests mapped to their corresponding cognitive domain are presented 
in Table 1.  
Global Cognitive function: We used Mini Mental State Examination (MMSE) 
(Folstein, Folstein, & McHugh, 1975), an 11-item validated screening tool, to evaluate 
the global cognitive function of the participants, including the orientation to place and 
time, short-term memory, language, comprehension, attention, and language ability of 
the individual. MMSE has a maximum score of 30, and a score equal to or below 23 
served as an exclusion criterion since it is indicative of cognitive impairments. In 
addition to the global cognitive function,  
  Verbal Memory: To assess this cognitive domain, the Free and Cued Selective 
Reminding Test (FCSRT) (Buschke, 1984; Ellen Grober & Buschke, 1987; E. Grober et 
al., 2008) was used. FCSRT is a 16-item assessment with six components. The first 
three components are immediate and measure free recall, total recall (sum of free and 
cued recalls), and cue efficiency, measured by the ratio of the recalls as a result of a 
cue over the number of items that were not initially recalled (% of cued recalls). The test 
is administered three times, and the score for free recall and total recall components is 
derived according to the sum of the three trials (range: 0-48). After 30 minutes of non-
verbal activities, the participants are required to perform the same test – only once – 
and the free delayed recalls, total delayed recalls and percentage of cued delayed 
recalls (delayed recall cue efficiency) were measured.  
Executive Function: This domain was assessed using the Color Word 
Interference Test – a subtest of Delis–Kaplan Executive Function Scale (D-KEFS) 




Individual Test Battery, 1944). The Color Word Interference Test evaluates the 
individual’s ability to shift cognitive focus and deal with conflicting stimuli and consists of 
four different components including color naming, word reading, inhibition, and flexibility. 
Color naming consists of calling the color of a series of colored boxes printed on a 
paper as quick as possible without making mistakes and evaluates the speech motor 
function. In word reading section, which also evaluates speech motor function, 
participants are asked to read a series of color words which are printed in black and 
white. In verbal inhibition component participants are presented with a series of color 
words printed in conflicting colors and are asked to say the color of the ink – a task that 
requires performance of a less automatic task (calling the color) and inhibition of a more 
automatic task (reading the word). Finally, in cognitive flexibility, participants are 
presented with a set of color words printed in conflicting colors, half of which are 
enclosed in a box and are asked to call the color of the words for the ones that appear 
without a box enclosing them and to read the words out loud for the ones that a box 
encloses them. Each component yields in a completion time as well as a scaled score 
which is based on the normative data with a mean of 10 and standard deviation of 3, 
accounting for age. In addition, the total number of errors made during the four 
components was calculated. The trail making test consist of two parts and measures the 
cognitive flexibility and task switching ability. In part A of TMT, individuals are presented 
with numbers ranging 1-25 which are distributed randomly on a paper and are asked to 
connected them in an ascending order as fast as possible without lifting the pen. In Part 
B, instead of the numbers only, they are presented with a mix of numbers (1-13) and 




between digits and letters (e.g. 1-A-2-B-3-C-4-D, etc.).  Each component is scored 
individually based on the number of seconds taken to complete the task, and the z-
score for each is calculated accounting for age and education levels. 
Attention and Concentration: In order to evaluate the attention and 
concentration, participants completed the Digit Symbol Substitution Test (DSST) 
(Wechsler, 1981). In this assessment, subjects are presented with an array of 9 
numbers each paired with a specific symbol, and are asked to note down the 
corresponding symbol for a long list of numbers randomly assorted for (a total of 140 
numbers). The performance is scored based on the number of correct associations 
completed within 90 seconds.  
Visuospatial Abilities: this was assessed using the Modified Taylor Complex 
Figure (MTCF) (Taylor, 1969), an assessment that requires the subjects to reconstruct a 
complex drawing presented to them. MTCF has two components, recognition and 
immediate recall. During the recognition part, participants are asked to copy a drawing 
by looking at it, while in immediate recall they reconstruct the same drawing from 
memory. The scores for this test include time taken to complete the recognition phase 
(copy time), as well as the accuracy of the recognition phase drawing (copy score) and 
immediate recall drawing (immediate recall score) calculated based on its location, 
accuracy, and organization. We obtained z-scores for copy and immediate recall scores 
accounting for age, sex, and education levels (SES z-score), given their documented 
effect on these two MTCF components (Tremblay et al., 2015). In addition, it has been 
shown that the copy time correlates with both copy and immediate recall scores, while 




reason, we also calculated z-scores (all variable z-score) for copy scores accounting for 
age, sex, education levels, and copy time; For immediate recall scores, we accounted 
for the same covariates plus copy score.  
Psychomotor Performance and Manual Dexterity: Using Purdue Pegboard 
test (Tiffin, 1968) we assessed the psychomotor performance and manual coordination. 
Participants are presented with a pegboard consisting of two rows of 25 holes, and are 
asked to place as many metal pegs as possible into the holes within a 30-second period 
using the dominant hand only, non-dominant only, and both hands. The score for each 
condition was calculated based on the number of rods (pairs of rods in case of bimanual 
component) placed in 30 seconds, and the z-scores accounted for age and sex.  
  
Group assignment  
After the baseline evaluations, participants were stratified into two groups of 
CBT-i and waitlist (delayed CBT-i), according to age, sex, medication type and duration, 
as well as education level. Given the nature of the CBT-i group therapy, and the need 
for the participants to interact with each other, each group consisted of 4 – 6 
participants. The first cohort of the study was not matched for the education level. 
 
Weaning protocol 
 All of the participants, regardless of their group assignment, went through a 16-
week weaning protocol adapted from the randomized trial developed by Tannenbaum et 
al. in 2014 (Tannenbaum, Martin, Tamblyn, Benedetti, & Ahmed, 2014). The subjects 




the risks of benzodiazepines, details on the possible side effects related to consumption 
of benzodiazepines, information about the possible drug interactions, alternative options 
for more efficient therapeutic substitutes, info on sleep hygiene, withdrawal success 
stories to increase the motivation, compliance and self-efficacy, as well as a step-by-
step weaning plan. The de-prescription plan was visually presented in the information 
package, directing the participants to gradually decrease the dose of the medication 
from full pill to half and then to a quarter pill dose and eventually stop taking the 
medication completely. This intervention was personalized based on the type and the 
dose of the benzodiazepines that the patients were consuming. In order to facilitate the 
accessibility, all of the information included in the package were written in the language 
set at a 6th grade reading level and the participants were asked to discuss these 
recommendations with their physician or pharmacist. During the weaning intervention, 
we conducted biweekly telephone follow-ups in order to encourage the patients to 
continue following the guidelines, record their compliance to the protocols, and 
document any possible withdrawal symptoms.  
 
CBT-i protocol 
Concurrently with the weaning, only the participants in the CBT-i group received 
CBT-i therapy offered in small groups of 4-6 people, as recommended by the literature 
(Bastien, Morin, Ouellet, Blais, & Bouchard, 2004; C. M. Morin et al., 1999). The 
intervention consisted of eight 90-minute therapy sessions. The first four sessions were 
offered every week, and the remaining four were separated 2 weeks apart, resulting in a 




behavioral, cognitive, and educational dimensions. The behavioral component was 
focused on educating the individuals to associate the bed only with sleeping and limit 
the time spent in the bedroom doing other activities. The cognitive component aimed to 
correct dysfunctional beliefs about insomnia and to limit the pre-sleeping negative 
thoughts that exacerbate insomnia. Finally, the educational component increased the 
individuals’ awareness about sleep hygiene and the normal physiological changes in 
sleep related to aging.  
Given the waitlist design of the study, participants in the waitlist group initially 
went through the weaning without the CBT-i therapy. However, at the end of the 
weaning and after completing the post intervention evaluations (described below) they 
were offered the opportunity to receive the CBT-i therapy. Interested participants, after 
going through the 16 weeks of the CBT-i therapy, completed another set of sleep and 
neuropsychological evaluations similar to the ones done at the end of the weaning 
period.  
 
Post intervention evaluations   
 At the end of the 16-week weaning intervention (weaning and CBT-i therapy in 
the case of the CBT-i group), participants went through a similar set of comprehensive 
sleep and neuropsychological evaluations done at the baseline.  
 The sleep evaluations consisted of one in-lab PSG recording, actigraphy (14 
days), series of subjective sleep questionnaires (ISI, PSQI, ESS), sleep diaries (14 
days), and the anxiety and depression questionnaires (GAI, GDS). The 




Word Interference Test, DSST, Purdue Pegboard) except MTCF which was replaced by 
Rey-Osterrieth complex figure (ROCF), a test similar to MTCF in nature which only 
differs in the drawing template. The choice to replace MTCF with ROCF at post 
intervention evaluations was made to prevent the learning effect as a result of repeated 
administration. It is well documented in the literature that both tests result in comparable 
accuracy scores and hence could be used interchangeably (Hubley & Jassal, 2006; 
Hubley & Tremblay, 2002; Yamashita, 2006). In order to minimize the effect of time of 
the day on the cognitive performance, these tests were performed in the morning at a 
time similar to the one performed at the baseline. To avoid a bias in cognitive 




Dependent variables: The primary outcomes for our study were the subjective 
sleep quality measures including sleep diary (total sleep time, sleep onset latency, sleep 
efficiency and wake duration after sleep onset), ISI and PSQI scores. Due to the night to 
night variability of PSG data, and the small sample size for the actigraphy data, we 
treated these measures as secondary variables. Also, because of the limited sample 
size and the fact that the cognitive measures require some time after the therapy to 
improve, we treated neuropsychological measures as secondary variables. 
Independent variables: The independent variables of interest were CBT-i 





Statistical tests: The normality and variances of the data were analyzed and 
compared using Shapiro-Wilk and Analysis of variance (ANOVA). Demographics, sleep 
variables and cognitive performance of completers versus drop outs as well as CBT-i 
group versus waitlist were compared. We used independent t-test for demographics 
data, however, because of our small sample size and the fact that most of the sleep and 
cognitive variables of interest did not meet the normality assumptions, we used the 
Mann-Whitney U-test in order to compare the sleep and cognitive continuous variables 
at baseline. For discrete variables, we applied Pearson chi-square test, which is free of 
normality assumption.  
In order to evaluate the effect of weaning as well as the CBT-i intervention on the 
improvements in our primary and secondary dependent variables and given the lack of 
normality in our data, we chose to perform the Generalized estimating equations – a 
test that does not assume normality of data (Wang, 2014) – using time (weaning) and 
group as in between-subject factor, and age, sex, and education level as covariates. We 
modeled the main effect of weaning and group interaction and the statistical differences 
were compared using Wald chi-square test. The withdrawal success rate (dichotomous 
measure evaluating whether participants achieved a complete cessation or not) across 
the two groups was compared using Pearson chi square test and the change in 
benzodiazepine consumption dose, measured in lorazepam dose equivalence, using 
Generalized estimating equations with the model and the covariates mentioned earlier. 
Finally, in order to evaluate the effect of CBT-i on improvements in cognitive 
performance upon benzodiazepine withdrawal, with a larger power, we increased our 




waitlist who completed CBT-i after weaning, and evaluated the changes in cognitive 
performance from baseline to post-CBT-i using the Generalized Estimating Equations 
with a similar model to what described above. The significance in all of the analyses 





Sixty one participants showed interest and were screened, among which 31 were 
either not eligible according to our study criteria or withdrew their consent before 
starting the study and being assigned to either group: 8 participants had high levels of 
anxiety and depression; 7 either had stopped taking benzodiazepines at the time of 
screening or were not taking it chronically; 4 had sleep apnea; 3 had chronic physical 
pain; 3 lacked the time required to commit to study; 3 found the IUGM laboratory far to 
commute; one consumed high amount of alcohol regularly; one lost interest to 
participate; and one did not like to spend the night at the laboratory bedroom.   
Thirty participants met the inclusion criteria and were enrolled in the study, 
among which 6 dropped out after completing the baseline evaluations and being 
assigned to one of the two groups, due to the following reasons: one dropped out due to 
loss of interest; one moved permanently to United States; one fell sick and was not able 
to continue the study; one suddenly stopped benzodiazepine intake on their own at the 
baseline; and two were excluded due to apnea which was detected after completing the 
baseline evaluations. Only 24 participants completed the study and were included in the 
final analyses, half of which were part of the CBT-i group and the other half part of the 
waitlist. 
A comparison between the demographics, sleep measures and cognitive 
performance of the dropouts and the ones who completed the study is presented in 
Table 2. There were no significant differences between the demographic features of the 
two groups including age, sex ratio, education level, benzodiazepine intake duration and 




lower stage N2 NREM sleep duration (U=36.0, Z=-1.78, p=0.076) and percentage of 
total sleep time spent in stage N2 NREM sleep (U=38.0, Z=-1.67, p=0.095) among the 
dropout group while actigraphy did not reveal any differences. Subjective sleep 
questionnaires showed a higher sleep efficiency (U=31.0, Z=-2.13, p=0.034) and 
daytime somnolence (U=18.5, Z=-2.79, p=0.005) among the dropouts, as evidenced by 
sleep diary and ESS respectively. Moreover, there was a tendency for higher 
depression levels among the dropouts. In terms of the neuropsychological evaluations, 
none of the measures in any of the cognitive domains was found to be different across 
the two groups. 
 
Differences between the CBT-i and the Waitlist group at the baseline 
In order to ensure that the CBT-i and waitlist groups did not differ at the baseline, 
we compared their demographics data (Table 3), subjective and objective sleep 
measures, and anxiety and depression levels (Table 4), as well as their cognitive 
performance (Table 5) measured at the baseline. We found no significant differences 
between the demographic characteristics of the two groups including age, body mass 
index, the duration of benzodiazepines consumption, the weekly benzodiazepine dose 
consumed in equivalent lorazepam dose. However, we observed a trend for higher 
education levels in the CBT-i group (p=0.093), explainable by the fact that we did not 
match the participants for this measure in the first cohort of the study which consisted of 
five participants in the CBT-i group and four in the waitlist. The chi square test revealed 
no significant difference in terms of the sex distribution across the two groups, though 




higher prevalence of insomnia in females in the general population (Krishnan & Collop, 
2006). 
The objective sleep measures consisted of polysomnography recordings as well 
as actigraphy data. The polysomnography data was obtained from all of the participants 
and included the following variables: Sleep latency defined by the latency to stage N1 
NREM sleep, wake duration after sleep onset, total sleep time, durations and proportion 
of each sleep stage in reference to the total sleep time, sleep efficiency calculated by 
the ratio of total sleep time to the time in bed, as well as sustained sleep efficiency 
measured by the ratio of total sleep time over time in bed after sleep onset. After 
evaluating our data for presence of outliers using box plots, we excluded one participant 
in the waitlist group from the PSG analyses for being an extreme outlier (total sleep time 
of 51 minutes and a sleep efficiency of 12%). None of the polysomnography measures 
at the baseline showed to be different across the two groups (Table 4). In terms of the 
actigraphy measures, we failed to obtain the data for all of the participants due to some 
technical difficulties related to the Respironics software which resulted in loss of some 
data. The actigraphy data which consisted of sleep latency, wake duration after sleep 
onset, sleep efficiency, and total sleep time was calculated for 9 participants in the CBT-
i and 10 in the Wait-list group and did not reveal significant differences across the two 
groups (Table 4). None of the subjective sleep measures including any of the sleep 
diary variables (including sleep latency, duration, efficiency or wake after sleep onset), 
PSQI or ESS showed any differences, except the ISI which was higher among the 




The performance in neuropsychological evaluations was measured for all of the 
participants at the baseline and was compared across the two groups (Table 5). The 
global cognitive function measured by the MMSE was not different across the two 
groups. Sub-components of the FCSRT, did not show differences in verbal memory. In 
terms of the executive function, waitlist group showed a trend for a better performance 
in the color section of the D-KEFS Color Word Interference Test as measured by their 
naming speed (U=42.5, Z=-1.71, p=0.088) and score (U=43.0, Z=-1.69, p=0.090). In 
addition, in the reading component of this test, the waitlist group performed better as 
evidenced by a significant difference in the reading speed (U=35.5, Z=-2.11, p=0.035) 
and a marginal difference in the score (U=39.5, Z=-1.90, p=0.058). Other D-KEFS Color 
Word Interference Test sub-components as well as TMT A and B were similar across 
the two groups. Digit Symbol Substitution Test demonstrated no difference in the 
attention and concentration domains across the two groups. Visuospatial abilities were 
contrasted according to the MTCF subcomponents, which consisted of the copy time, 
copy score, recall score and their respective z-scores. No differences in the visuospatial 
abilities were observed. Finally, evaluating the Purdue Pegboard scores showed a trend 
for better manual dexterity in dominant hand of the waitlist group (U=41.0; Z=-1.82; 
p=0.069) while it’s z-score – accounting for age and sex – did not demonstrate such 
trend. 
 
Changes in Sleep measures following the intervention 
The result of our Generalized Estimating Equation analyses, evaluating the effect 




Table 6. All of the participants in the CBT-i group were included in the analyses for the 
PSG measures, while one participant in the waitlist was excluded for being an extreme 
outlier, yielding a sample size of 12 in CBT-i versus 11 in waitlist. Also, two participants 
in the waitlist group lost their sleep diaries at the end of the intervention and for this 
reason, waitlist consisted of 10 participants for the sleep diary measures. The technical 
difficulty with the Respironics software and the loss of actigraphy data resulted in 
sample size of seven in the CBT-i group and five in the waitlist for this measure. 
The effects of weaning and CBT-i on improvements in sleep measures are 
presented in Table 6. All of our primary sleep outcomes showed a significant interaction 
between weaning and CBT-i, except ISI. Subjective sleep quality measured by self-
reported sleep diaries showed a significant effect of CBT-i on improvements in sleep 
quality. Sleep latency (figure 3) and wake after sleep onset (figure 4) decreased in the 
CBT-i group while waitlist showed an increase in both measures, with a significant 
interaction for each, (Wald χ2=7.19; p=0.007) and (Wald χ2=8.32; p=0.004) 
respectively. Sleep efficiency (figure 5) in CBT-i group improved while it deteriorated in 
the waitlist group, with a significant interaction effect (Wald χ2=16.78; p=0.000). Total 
sleep time (figure 6) also highlighted a significant interaction (Wald χ2=6.94; p=0.008) 
as this measure increased for the CBT-i group while it decreased for the waitlist. Sleep 
quality, measured by PSQI (figure 7), improved in both groups (Wald χ2=9.47; 
p=0.002), but was more prominent in CBT-i group with significant interaction effect 
(Wald χ2=5.98; p=0.014). ISI decreased in both groups (figure 8) (significant effect of 




in the CBT-i group, as evidenced by a trend for the interaction effect (Wald χ2=2.72; 
p=0.099). 
In terms of the secondary sleep outcomes, polysomnography data showed a 
significant effect of weaning on increasing the wake after sleep onset (figure 9) (Wald 
χ2=4.39; p=0.036) and a trend for decreased sustained sleep efficiency (Wald χ2=2.96; 
p=0.086) in both groups. Additionally, both groups showed a trend for a decrease in 
duration of stage N2 NREM sleep (Wald χ2=3.13; p=0.077) and an increase in stage N3 
NREM sleep duration (Wald χ2=3.45; p=0.063) which turned significant when evaluated 
in terms of its proportion to total sleep time (Wald χ2=4.12; p=0.042) (figure 10).  No 
group interaction was found in terms of the PSG data. On the other hand, the actigraphy 
data, as another objective sleep measure, highlighted a significant effect of CBT-i on 
sleep improvements. Wake after sleep onset (figure 11) decreased in the CBT-i group 
while it increased in the waitlist, with a significant interaction between CBT-i and 
weaning (Wald χ2=7.03; p=0.008). Sleep efficiency derived from actigraphy also 
evidenced a significant interaction effect (Wald χ2=13.72; p=0.000), as the CBT-i group 
improved in this measure and waitlist deteriorated (figure 12). 
While no significant change was observed for anxiety levels across the two 
groups, we found a trend for an interaction effect in terms of the Geriatric Depression 
Scale (Wald χ2=3.10; p=0.078), due to decreased depression levels among the waitlist 





Changes in cognitive performance in different domains following the intervention 
 We evaluated the effect of weaning and CBT-i on improvements in cognitive 
performance in the two groups using the same model as the one mentioned before and 
the results are presented in the table 7. All of the participants in the CBT-i group (n=12) 
and the waitlist (n=12) were included in the analyses. 
We did not find any differences in terms of the global cognitive function as 
measured by the MMSE. In terms of the executive function, reading speed (measured 
by the D-KEFS Color Word Interference Test) increased in the CBT-i group while it 
worsened in the waitlist, highlighting interaction effects for both test duration (Wald 
χ2=12.38; p=0.000) (figure 13) and score (Wald χ2=7.53; p=0.006) (figure 14). Both 
groups showed a decline in delayed verbal fluency as evidenced by a trend in effect of 
weaning on the FCSRT delayed total recall score (Wald χ2=2.72; p=0.099) and a 
significant effect on the FCSRT delayed recall cue efficiency (Wald χ2=4.63; p=0.032) 
(figure 15). Visuospatial abilities were measured by MTCF and ROCF. Both groups 
showed improvements in their copying accuracy as measured by Copy score (Wald 
χ2=5.99; p=0.014) (figure 16), SES z-score (Wald χ2=6.17; p=0.013) (figure 17), and all 
variable z-score (Wald χ2=6.59; p=0.010) (figure 18), however, the improvements 
observed were more pronounced in the waitlist group (Copy score (Wald χ2=4.18; 
p=0.041), SES z-score (Wald χ2=4.33; p=0.037), and all variables z-score (Wald 
χ2=4.35; p=0.037)). On the other hand, the immediate recall component of the 
MTCF/ROCF test, corrected for all variables, evidenced a significant interaction effect 
on the visuospatial domain as the CBT-i improved significantly in this measure while the 




performance, although both groups improved in their non-dominant hand dexterity, 
measured by the Purdue Pegboard z-score (Wald χ2=5.15; p=0.023) (figure 20), 
bimanual dexterity showed a tendency for improvement in the waitlist and deterioration 
in the CBT-i group (Wald χ2=3.19; p=0.074). 
  
Withdrawal success rates and changes in medication dosage 
The benzodiazepine medication dose consumed prior to and after the 
intervention was calculated in weekly doses for each participant and for the sake of 
comparisons, were converted to equivalent lorazepam dose. Overall, 15 out of the 24 
participants (62.50%) succeeded to fully stop their medication immediately after the 
intervention. No significant difference was observed in the withdrawal success rate 
between the CBT-i (66.66%) and the waitlist (58.33%) group, as measured by the 
Pearson chi-square test (χ2 value=0.178; df=1; p=0.673).  
In order to evaluate the effect of weaning and CBT-i on the changes in the 
medication dosage, we performed the Generalized Estimating Equations as explained 
above, which evidenced a significant reduction in medication consumption dose in both 
groups (Wald χ2=18.07; p=0.000), as the benzodiazepine dose, calculated in weekly 
equivalent lorazepam dose, decreased in both CBT-i group (from 67.60±69.48mg to 
30.78±75.09mg) and the waitlist (from 95.89±140.11mg to 17.61±30.08mg). However, 





Changes in cognitive performance in different domains in pooled CBT-i group 
Our secondary analyses, evaluating the combined effect of CBT-i and weaning 
on changes in cognitive measures, within our pooled sample, are presented in table 7. 
Combined CBT-i and weaning in this sample showed to have a positive effect in 
improving immediate verbal memory, measured by the FCSRT – Free recall (Wald 
χ2=4.92; p=0.027). On the other hand, the cue efficiency was found to decrease in the 
delayed component of the FCSRT (Wald χ2=4.25; p=0.039). In terms of the executive 
function, we found a tendency for a decrease in total number of errors made in the four 
components of the D-KEFS Color Word Interference Test (Wald χ2=3.24; p=0.072). 
Digit Symbol Substitution Test, measuring attention and concentration domains was 
found to improve with a marginal significance (Wald χ2=3.52; p=0.061) upon completion 
of the weaning and CBT-i. We found a tendency for improvements in visuospatial 
abilities as shown in both immediate recall component of MTCF/ROCF score (Wald 
χ2=2.93; p=0.087) and SES z-score (Wald χ2=3.26; p=0.071). Finally, manual dexterity 
improved in the non-dominant hand, evidenced by a trend in the Purdue Pegboard 








All of the 24 participants completed the study, however, two in the waitlist group 
lost their post intervention sleep diary, one was excluded from the PSG analyses for 
being an extreme outlier, and actigraphy recordings for 12 participants were lost due to 
a software problem. Our comparison between the completers and drop-outs revealed 
that in terms of sleep measures drop-outs had higher sleep efficiency and higher 
daytime somnolence and slightly higher depression levels while they did not differ in 
cognitive measures compared to the completers. Although it could be speculated that 
higher sleep efficiency could translate to lower desire to seek treatment and hence 
explain the reason for dropping out, but in our sample the reasons for dropping out were 
diverse and mostly irrelevant to the sleep characteristics of these participants (e.g., 
falling sick, moving away, being excluded due to sleep apnea). For most parts, the data 
pertaining to the variables of interest were not normally distributed which forced us to 
perform a statistical test independent from normality of the data (Generalized Estimating 
Equations).  
Our data suggest that CBT-i can help improve sleep quality in a population of 
elderly insomniacs who are weaning from benzodiazepines, further to the effect of 
variations in age, sex, and education levels. The effect of CBT-i was evident in 
improving our primary variables of interest. All of the sleep diary measures including 
sleep latency, wake after sleep onset, sleep efficiency, and total sleep time improved in 
the CBT-i group at the end of the intervention while they all deteriorated in the waitlist 
group. PSQI improved in both groups, however, this improvement was more prominent 




reported in other studies as well (Petrovic, Pevernagie, Mariman, Van Maele, & 
Afschrift, 2002). Insomnia severity index improved upon weaning in both groups – in line 
with the previous findings (Petrovic et al., 2002) –  and the CBT-i group showed a trend 
for more improvements in this measure compared to the waitlist. Given that previous 
studies reported significant interaction between weaning and CBT-i (C. M. Morin et al., 
2004), we hypothesize that the absence of such effect could be due to the differences in 
ISI values of the two groups at the baseline; the changes in ISI should be interpreted 
cautiously as the CBT-i group had lighter insomnia symptoms (lower ISI scores) at 
baseline.   
Our secondary variables of interest evaluating objective sleep quality also 
supported the efficacy of CBT-i in improving sleep quality, although not as extensive as 
the subjective sleep quality. Actigraphy measures of sleep efficacy and wake after sleep 
onset improved in the CBT-i group and deteriorated in the waitlist, in line with our sleep 
diary findings. None of the polysomnography measures highlighted an effect for CBT-i, 
which could be explained by the day-to-day variability of PSG data. On the other hand, 
polysomnography recordings highlighted the effect of weaning alone, on sleep 
measures. Wake after sleep onset increased and there was a trend for decreased 
sustained sleep efficiency in both groups. This could be explained due to reduction in 
the dose of sedatives consumed in both group and a subsequent increase in 
vulnerability to external stimuli and disturbing factors, especially when spending the 
night sleeping in a laboratory with a series of electrodes mounted on the head and face. 
Weaning alone also affected the sleep macro-architecture as stage N3 NREM sleep 




Withdrawal from benzodiazepines, which has been shown to suppress deep sleep (C. 
M. Morin et al., 2004), can explain the increase in proportion of sleep spent in stage N3 
NREM sleep. The trend for decreased stage N2 NREM sleep could be a compensatory 
change as a result of increased deep sleep.  
 
We chose to evaluate the improvements in cognitive performance of the 
subjects, from baseline to post-intervention, in the domains are affected in insomniacs 
or chronic benzodiazepine users. Insomnia has been consistently associated with 
declines in various cognitive domains including attention and concentration (Fortier-
Brochu & Morin, 2014; Owsley, Burton-Danner, & Jackson, 2000; Persad, Abeles, 
Zacks, & Denburg, 2002), executive functioning (Fortier-Brochu et al., 2012; Haimov, 
Hanuka, & Horowitz, 2008; Mattay et al., 2006), episodic memory (Fortier-Brochu & 
Morin, 2014), working memory (Fortier-Brochu et al., 2012), and problem solving 
abilities (Fortier-Brochu et al., 2012). A recent study investigating the correlation 
between subcortical changes in chronic insomniacs and their cognitive functioning 
evidenced hippocampal atrophy and PSQI scores highlighted atrophic regions in 
amygdala, basal ganglia and thalamus that were associated with worse verbal and 
visuospatial memory (Koo, Shin, Lim, Seong, & Joo, 2017). Similarly, chronic use of 
benzodiazepines is shown to be detrimental for cognition in various domains including 
attention and concentration (Golombok et al., 1988; Petursson, Gudjonsson, & Lader, 
1983), Verbal memory (Tata, Rollings, Collins, Pickering, & Jacobson, 1994), 
psychomotor (Gorenstein, Bernik, & Pompeia, 1994; Lucki, Rickels, & Geller, 1986; 




1980; Golombok et al., 1988; Sakol & Power, 1988; Tata et al., 1994). CBT-i, on the 
other hand, is shown to improve cognition in attention, concentration, and executive 
functioning (Miro et al., 2011). 
Our study was unique in a sense that to the best of our knowledge no other study 
investigated the effect of CBT-i on cognition upon weaning from benzodiazepines, in an 
elderly population. We observed an effect for CBT-i on improving the executive function, 
measured by the reading component of the D-KEFS Color Word Interference Test, as 
the CBT-i group improved. Although it is plausible to think that CBT-i had an effect on 
improvements in this domain, it could also be possible that lower executive performance 
at the baseline among the CBT-i group allowed more room for improvements in this 
measure. Weaning from benzodiazepines caused deteriorations in delayed verbal 
memory as both groups showed poorer performance in delayed recall cue efficiency of 
the FCSRT test, which was not in line with our initial hypotheses. Copying abilities – a 
subcomponent of visuospatial skills – improved in both groups, but contrary to our 
expectation, it improved more prominently among the controls. However, the recall 
component of the MTCF/ROCF, which is more challenging and requires patients to 
draw from memory, showed significant improvements among the CBT-i group while it 
deteriorated in the controls. Manual dexterity in non-dominant hand improved in both 
groups, while the controls marginally improved in terms of the bimanual dexterity. It is 
worthwhile to note that these results should be interpreted very cautiously as the small 
sample size limited the power of statistical tests, particularly with inclusion of covariates. 
Furthermore, one might argue that the improvements found in these measures could 




that these two measures were not different across the two groups at the baseline and 
did not change significantly from pre- to post intervention. Future studies with sample 
sizes large enough that allows including more covariates, should still evaluate whether 
the changes in anxiety and depression levels have any effects on the cognitive 
changes. 
Our findings related to cognitive changes were complex. We postulate that the 
lack of uni-directionality of the cognitive results could be due to the limited sample size, 
the baseline differences across the two groups, and the lack of time for cognitive 
measures to improve. In order to increase our statistical power and obtain a better 
impression of cognitive changes following benzodiazepine withdrawal complemented 
with CBT-i, we pooled the pre- and post-CBT-i data of both groups together and 
evaluated the changes in cognitive performance. With a larger sample size of 18, 
observed a different set of results. The number of errors made during the D-KEFS test 
(measuring the executive function) marginally decreased, and the attention and 
concentration showed a trend for increase. Verbal memory improved both in immediate 
and delayed components, manual dexterity improved in non-dominant hand, and the 
copying component of the MTCF/ROCF test showed a trend for improvement. Previous 
studies looking at the effect of benzodiazepine withdrawal demonstrated that cognitive 
improvements require a minimum of six months to reinstate (Barker et al., 2004b). 
Given this evidence, it is plausible to expect more concrete and coherent functional 
improvements in cognitive domains in longer terms follow-ups.  
Overall, 62.5% of the participants managed to completely wean from 




cessation success rates across the two groups. The high cessation success rate in the 
control group and similarity of this measure to the CBT-i group highlights the 
effectiveness of our structured weaning protocol. Achieving such high cessation 
success rate is particularly remarkable despite the worsened sleep measures evidenced 
in this group. A follow up study will be interesting to evaluate whether these patients 
remain benzodiazepine free in presence of worsened sleep quality or return to 
consuming these hypnotics to mask their insomnia symptoms.  
Our study was limited in many ways: the sample size of 12 versus 12 was small 
and the statistical tests could have potentially been underpowered, particularly with the 
inclusion of the covariates. The skewness of the variables of interest and lack of 
normality of data could also be explained in parts by the limited sample size. Although 
the group assignment was not stratified based on ISI, the CBT-i group ended up having 
lighter insomnia symptoms at baseline, which could explain the improvements in sleep 
measures in this group. We expect that addition of more participants shall mask the 
differences in ISI at baseline. Previous studies have suggested allowing at least 6 
months for the cognitive measures to improve upon withdrawing from benzodiazepines. 
Follow-up neuropsychiatric evaluations at 6 months and 1 year with larger sample size 
would have allowed us to draw more concrete conclusions about the changes in 
cognitive performance. Also, the low number of errors made in the D-KEFS executive 
function could suggest that some of the cognitive tests might have not been difficult 
enough to differentiate subtle improvements in certain cognitive domains.  
Here we demonstrate that a structured benzodiazepine withdrawal program can 




complementing this withdrawal with CBT-i can be very beneficial in terms of improving 
the sleep quality in this population. However, the role of CBT-i on cognitive 
performance, when complementing the withdrawal, is not very clear. Future studies with 
larger sample size, should evaluate the benefits of CBT-i in a structured benzodiazepine 
withdrawal program on cognitive performance, after allowing ample time for changes in 






Table 1. Neuropsychological tests performed mapped to their corresponding cognitive domain 
Cognitive Domain  Neuropsychological Test 
Global Cognitive Function  Mini-Mental State Exam (score) 
Executive Function D-KEFS Color Word Interference Test – Color (sec) 
 D-KEFS Color Word Interference Test – Color (score) 
 D-KEFS Color Word Interference Test – Reading (sec) 
 D-KEFS Color Word Interference Test – Reading (score) 
 D-KEFS Color Word Interference Test – Inhibition (sec) 
 D-KEFS Color Word Interference Test – Inhibition (score) 
 D-KEFS Color Word Interference Test – Flexibility (sec) 
 D-KEFS Color Word Interference Test – Flexibility (score) 
 D-KEFS Color Word Interference Test – Total Number of Errors 
 Trail Making Test – Part A (sec) 
 Trail Making Test – Part A (z-score) 
 Trail Making Test – Part B (seconds) 
 Trail Making Test – Part B (z-score) 
Attention and Concentration Digit Symbol Substitution Test (score) 
Verbal Memory FCSRT – Free Recall (score) 
 FCSRT – Total Recall (score) 
 FCSRT – Cue Efficiency (%) 
 FCSRT – Delayed Free Recall (score) 
 FCSRT – Delayed Total Recall (score) 
 FCSRT – Delayed Recall Cue Efficiency (%) 
Visuospatial Skills MTCF/ROCF – Copy (sec) 
 MTCF/ROCF – Copy (score) 
 MTCF/ROCF – Copy (z-score corrected for SES) 
 MTCF/ROCF – Copy (z-score corrected for All variables) 
 MTCF/ROCF – Immediate Recall (score) 
 MTCF/ROCF – Immediate Recall  (z-score corrected for SES) 
 MTCF/ROCF – Immediate Recall  (z-score corrected for All variables) 
Motor Skills Purdue Pegboard Dominant Hand (Score) 
 Purdue Pegboard Dominant Hand (z-score) 
 Purdue Pegboard – Non-Dominant Hand (Score) 
 Purdue Pegboard – Non-Dominant Hand (z-score) 
 Purdue Pegboard – Both Hands (score) 





Table 2. Comparison between demographics, sleep and cognitive measures of the completers 








t value p value 
Demographics 
Age (years) 69.29±7.18 66.33±2.73 2.96 0.98 0.335 
Sex (M:F) 8:16 1:5   0.426 
Education Level (years) 15.38±3.03 15.17±3.13 0.21 0.15 0.882 
Body Mass Index (kg/m2) 25.12±4.56 27.08±1.33 -1.96 -1.03 0.311 
Medication Duration (years) 13.67±11.86 5.25±6.06 8.42 1.67 0.106 
Weekly Benzodiazepine dose 
(lorazepam dose equivalence)  
81.74±109.12 20.42±18.42 61.33 1.35 0.186 
Parameters 
Completers 
(n= 24; PSG n=23; 
Acti n=19) 
Drop-Outs 
(n=6; Acti n=5) 
Test U  Z value p value 
 
Sleep Measures 
Sleep Diary Measures       
     Sleep Latency (min) 41.67±34.67 30.28±32.94 55.5 -0.86 0.392 
     Wake After Sleep Onset (min) 48.44±42.72 20.03±17.34 37.0 -1.81 0.070 
     Sleep Efficiency (%) 79.77±10.85 89.86±7.47 31.0 -2.13 0.034* 
     Total Sleep Time (min) 402.48±81.05 422.89±37.89 60.0 -0.62 0.534 
Pittsburgh Sleep Quality Index  11.33±3.77 9.83±4.02 57.5 -0.76 0.448 
Insomnia Severity Index  14.54±5.45 13.33±4.37 63.0 -0.47 0.640 
Epworth Sleepiness Scale  4.83±2.63 10.83±5.67 18.5 -2.79 0.005* 
Geriatric Anxiety Inventory 6.17±5.39 9.83±6.97 47.5 -1.28 0.201 
Geriatric Depression Scale 12.17±3.48 14.50±2.59 36.5 -1.85 0.064 
Polysomnography Measures      
     Sleep Latency (min)  19.60±20.91 19.17±19.67 64.0 -0.27 0.788 
     Wake After Sleep Onset (min)  100.99±72.30 70.55±41.09 50.0 -1.02 0.306 
     Sleep Efficiency (%) 74.18±16.36 81.07±10.21 52.0 -0.92 0.360 
     Sustained Sleep Efficiency (%) 77.15±16.64 83.85±10.46 47.0 -1.18 0.236 
     Total Sleep Time (min) 354.67±101.34 377.61±81.48 68.0 -0.05 0.957 
     N1 Duration (min) 42.21±23.15 34.06±20.37 58.0 -0.59 0.554 
     N1 % of TST (%) 13.75±12.06 10.30±7.36 58.0 -0.59 0.554 




     N2 % of TST (%) 58.47±9.78 52.97±8.16 38.0 -1.67 0.095 
     N3 Duration (min) 43.35±33.27 62.30±62.33 65.0 -0.22 0.829 
     N3 % of TST (%) 11.47±8.51 16.23±13.15 58.0 -0.59 0.554 
     REM Duration (min) 55.94±31.24 69.55±43.45 59.0 -0.54 0.590 
     REM % of TST (%) 14.39±7.07 20.50±7.30 42.5 -1.43 0.153 
Actigraphy Measures      
     Sleep Latency (min) 43.41±32.79 35.08±26.17 40.0 -0.53 0.594 
     Wake After Sleep Onset (min) 40.90±20.01 29.87±10.08 29.0 -1.32 0.189 
     Sleep Efficiency (min) 80.86±7.07 82.37±4.71 46.0 -0.11 0.915 
     Total Sleep Time (min) 413.47±60.79 391.80±38.31 32.0 -1.10 0.270 
Cognitive Measures 
Mini-Mental State Exam (score) 
28.29±2.22 28.17±1.83 67.0 -0.27 0.787 
D-KEFS Color Word Interference Test 
– Color (sec) 
31.17±7.09 26.67±4.08 42.0 -1.56 0.119 
D-KEFS Color Word Interference Test 
– Color (score) 
10.83±2.71 12.00±2.00 56.5 -0.81 0.416 
D-KEFS Color Word Interference Test 
– Reading (sec) 
22.50±4.39 22.00±3.85 68.5 -0.18 0.855 
D-KEFS Color Word Interference Test 
– Reading (score) 
11.25±2.25 11.33±1.97 72.0 0.00 1.000 
D-KEFS Color Word Interference Test 
– Inhibition (sec) 
66.46±18.46 59.00±5.18 59.5 -0.65 0.516 
D-KEFS Color Word Interference Test 
– Inhibition (score) 
11.21±2.54 11.83±0.75 66.0 -0.32 0.753 
D-KEFS Color Word Interference Test 
– Flexibility (sec) 
67.88±17.07 70.50±32.02 63.0 -0.47 0.641 
D-KEFS Color Word Interference Test 
– Flexibility (score) 
11.67±2.01 11.17±4.54 63.0 -0.47 0.637 
D-KEFS Color Word Interference Test 
– Total Number of Errors   
2.67±2.68 2.67±4.27 57.5 -0.76 0.445 
Trail Making Test – Part A (sec) 
41.83±11.68 42.67±17.39 67.0 -0.26 0.795 
Trail Making Test – Part A (z-score) 
0.64±1.32 1.21±2.64 66.5 -0.29 0.775 
Trail Making Test – Part B (seconds) 
107.79±77.31 101.83±78.79 51.5 -1.06 0.288 
Trail Making Test – Part B (z-score) 
1.02±2.42 3.19±8.67 56.0 -0.83 0.407 
Digit Symbol Substitution Test (score) 
44.21±9.91 48.50±10.78 58.0 -0.73 0.466 
FCSRT – Free Recall (score) 
30.75±5.37 28.50±8.22 63.5 -0.44 0.659 
FCSRT – Total Recall (score) 
45.75±2.66 44.83±4.96 69.5 -0.13 0.894 
FCSRT – Cue Efficiency (%) 
89.90±12.45 88.28±15.01 65.0 -0.37 0.710 
FCSRT – Delayed Free Recall (score) 
12.21±2.40 10.33±3.67 49.0 -1.20 0.229 
FCSRT – Delayed Total Recall (score) 




FCSRT – Delayed Recall Cue 
Efficiency (%) 
97.00±5.88 91.12±14.39 56.0 -0.93 0.351 
MTCF – Copy (sec) 
160.58±43.31 140.83±41.28 49.5 -1.17 0.243 
MTCF – Copy (score) 
31.58±2.41 31.17±1.17 59.0 -0.68 0.495 
MTCF – Copy (z-score corrected for 
SES) 
0.07±0.69 -0.12±0.40 56.0 -0.83 0.407 
MTCF – Copy (z-score corrected for All 
variables) 
-0.03±0.71 -0.24±0.42 54.0 -0.93 0.351 
MTCF – Immediate Recall (score) 
16.38±5.07 14.75±3.56 56.0 -0.83 0.406 
MTCF – Immediate Recall  (z-score 
corrected for SES) 
0.12±0.93 -0.19±0.58 55.0 -0.88 0.378 
MTCF – Immediate Recall  (z-score 
corrected for All variables) 
-0.24±1.01 -0.65±0.49 53.0 -0.99 0.325 
Purdue Pegboard Dominant Hand 
(Score) 
12.67±1.74 13.00±3.22 68.0 -0.21 0.833 
Purdue Pegboard Dominant Hand (z-
score) 
-0.16±1.07 -0.68±2.15 57.5 -0.75 0.452 
Purdue Pegboard – Non-Dominant 
Hand (Score) 
12.25±1.36 13.50±2.74 44.0 -1.48 0.138 
Purdue Pegboard – Non-Dominant 
Hand (z-score) 
-0.14±0.70 -0.03±1.94 56.0 -0.83 0.406 
Purdue Pegboard – Both Hands 
(score) 
10.00±1.47 10.00±1.55 68.0 -0.21 0.831 
Purdue Pegboard – Both Hands (z-
score) 
0.25±1.44 0.09±2.06 58.5 -0.70 0.483 
Means ± standard deviations are presented and statistically compared using independent t-
test (demographics data except Sex) or Generalized Estimating Equations (sleep and 
cognitive measures). For differences in sex distribution, which used Pearson’s χ2 test. 
*denotes statistical significance at p<0.05. 
Abbreviations: D-KEFS, Delis-Kaplan Executive Function System; FCSRT, Free and Cued 
Selective Reminding Test; MTCF, Modified Taylor Complex Figure; REM, Rapid Eye 












t value p value 
Age (years) 71.58±7.46 67.00±6.37 4.58 1.62 0.120 
Sex (M:F) 5:7 3:9   0.386 
Education Level (years) 16.42±13.32 14.33±2.42 2.08 1.76 0.093 
Body Mass Index (kg/m2) 25.87±4.86 24.38±4.31 1.49 0.80 0.435 
Medication Duration (years) 15.00±13.02 12.335±10.99 2.67 0.54 0.593 
Weekly Benzodiazepine dose 
(lorazepam dose equivalence)  
67.60±69.48 95.88±140.11 -28.28 -0.63 0.537 
Means ± standard deviations are presented and statistically compared using independent t-






















Test U  Z value p value 
Sleep Diary      
     Sleep Latency (min) 42.51±34.67 40.83±36.20 68.0 -0.23 0.817 
     Wake After Sleep Onset (min) 44.48±43.97 52.40±43.00 58.5 -0.78 0.436 
     Sleep Efficiency (%) 72.39±25.01 80.12±11.15 68.0 -0.23 0.817 
     Total Sleep Time (min) 403.75±75.94 401.20±89.24 71.0 -0.06 0.954 
Pittsburgh Sleep Quality Index  11.33±4.31 11.33±3.34 69.0 -0.18 0.861 
Insomnia Severity Index  12.25±5.46 16.83±4.55 33.0 -2.26 0.024* 
Epworth Sleepiness Scale  4.75±2.70 4.92±2.68 72.0 0.00 1.000 
Geriatric Anxiety Inventory  5.33±5.23 7.00±5.64 58.0 -0.81 0.415 
Geriatric Depression Scale  11.25±2.26 13.08±4.29 53.5 -1.08 0.281 
Polysomnography Measures       
     Sleep Latency (min)  21.32±25.73 18.33±16.37 63.0 -0.18 0.854 
     Wake After Sleep Onset (min)  89.50±52.43 87.78±24.92 58.0 -0.49 0.622 
     Sleep Efficiency (%) 76.82±10.58 76.93±9.64 63.5 -0.15 0.878 
     Sustained Sleep Efficiency (%) 80.03±10.64 79.95±8.10 61.0 -0.31 0.758 
     Total Sleep Time (min) 359.11±74.00 377.40±88.32 54.5 -0.71 0.479 
     N1 Duration (min) 39.13±27.87 46.49±18.35 50.0 -0.99 0.325 
     N1 % of TST (%) 11.16±7.84 12.18±4.73 53.0 -0.80 0.424 
     N2 Duration (min) 215.14±49.58 228.01±47.83 59.0 -0.43 0.667 
     N2 % of TST (%) 59.91±6.02 58.76±11.62 65.0 -0.06 0.951 
     N3 Duration (min) 47.08±32.25 43.23±34.59 58.0 -0.49 0.622 
     N3 % of TST (%) 13.38±9.01 10.44±7.66 52.0 -0.86 0.389 
     REM Duration (min) 57.45±23.73 59.38±36.00 55.0 -0.68 0.498 
     REM % of TST (%) 15.55±4.55 14.43±8.36 63.0 -0.18 0.853 
Actigraphy Measures      
     Sleep Latency (min) 40.09±34.54 46.40±32.70 38.0 -0.57 0.568 
     Wake After Sleep Onset (min) 39.75±18.65 41.94±22.12 42.0 -0.24 0.806 
     Sleep Efficiency (min) 82.10±7.93 79.75±6.41 30.0 -1.22 0.221 
     Total Sleep Time (min) 434.56±45.61 394.50±68.53 27.5 -1.43 0.153 
Means ± standard deviations are presented and statistically compared using Generalized 
Estimating Equations. * denotes statistical significance at p<0.05. Primary outcome 
parameters are bolded. 










Test U  Z value p value 
Mini-Mental State Exam (score) 28.33±1.78 28.25±2.67 65.0 -0.43 0.670 
D-KEFS Color Word Interference Test – Color 
(sec) 
32.83±6.48 29.50±7.56 42.5 -1.71 0.088 
D-KEFS Color Word Interference Test – Color 
(score) 
10.25±2.30 11.42±3.06 43.0 -1.69 0.090 
D-KEFS Color Word Interference Test – 
Reading (sec) 
24.25±3.84 20.75±4.35 35.5 -2.11 0.035* 
D-KEFS Color Word Interference Test – 
Reading (score) 
10.42±2.02 12.08±2.23 39.5 -1.90 0.058 
D-KEFS Color Word Interference Test – 
Inhibition (sec) 
69.55±18.32 63.17±18.81 51.5 -1.18 0.236 
D-KEFS Color Word Interference Test – 
Inhibition (score) 
11.00±2.66 11.42±2.50 67.0 -0.29 0.771 
D-KEFS Color Word Interference Test – 
Flexibility (sec) 
71.50±17.67 64.25±16.38 52.5 -1.13 0.260 
D-KEFS Color Word Interference Test – 
Flexibility (score) 
11.08±2.27 12.25±1.60 52.0 -1.18 0.239 
D-KEFS Color Word Interference Test – Total 
Number of Errors   
2.75±2.34 2.58±3.09 63.0 -0.53 0.598 
Trail Making Test – Part A (sec) 42.33±12.71 41.33±11.11 71.5 -0.03 0.977 
Trail Making Test – Part A (z-score) 0.43±0.90 0.86±1.66 65.0 -0.40 0.686 
Trail Making Test – Part B (seconds) 110.92±72.45 104.67±85.01 55.0 -0.98 0.326 
Trail Making Test – Part B (z-score) 1.20±3.12 0.83±1.56 59.0 -0.75 0.453 
Digit Symbol Substitution Test (score) 42.50±9.12 45.92±10.77 61.0 -0.64 0.524 
FCSRT – Free Recall (score) 30.33±6.30 31.17±4.49 63.5 -0.49 0.623 
FCSRT – Total Recall (score) 45.75±2.60 45.75±2.83 66.0 -0.36 0.721 
FCSRT – Cue Efficiency (%) 88.89±12.27 90.92±13.10 60.5 -0.68 0.495 
FCSRT – Delayed Free Recall (score) 11.92±2.15 12.50±2.68 58.5 -0.79 0.431 
FCSRT – Delayed Total Recall (score) 15.75±0.45 15.83±0.39 66.0 -0.49 0.623 
FCSRT – Delayed Recall Cue Efficiency (%) 96.38±6.62 97.69±5.19 60.0 -0.51 0.609 
MTCF – Copy (sec) 165.00±50.88 156.17±35.94 59.5 -0.72 0.470 
MTCF – Copy (score) 32.00±1.91 31.17±2.86 62.0 -0.58 0.560 
MTCF – Copy (z-score corrected for SES) 0.15±0.57 -0.01±0.81 65.0 -0.40 0.686 
MTCF – Copy (z-score corrected for All 
variables) 
0.06±0.57 -0.12±0.84 65.0 -0.40 0.686 
MTCF – Immediate Recall (score) 15.21±4.83 17.54±5.24 52.0 -1.16 0.247 
MTCF – Immediate Recall  (z-score corrected 
for SES) 
-0.10±0.90 0.35±0.95 55.5 -0.95 0.341 
MTCF – Immediate Recall  (z-score corrected 
for All variables) 
-0.55±0.90 0.07±1.06 46.0 -1.50 0.133 
Purdue Pegboard Dominant Hand (Score) 12.00±1.81 13.33±1.44 41.0 -1.82 0.069 
Purdue Pegboard Dominant Hand (z-score) -0.35±1.21 0.04±0.93 52.5 -1.13 0.260 
Purdue Pegboard – Non-Dominant Hand 
(Score) 
12.00±1.41 12.50±1.31 66.0 -0.36 0.720 
Purdue Pegboard – Non-Dominant Hand (z-
score) 
-0.16±0.88 -0.13±0.51 71.0 -0.06 0.954 
Purdue Pegboard – Both Hands (score) 9.92±1.68 10.08±1.31 68.5 -0.21 0.836 




Means ± standard deviations are presented and statistically compared using Generalized Estimating 
Equations. * denotes statistical significance at p<0.05. 
Abbreviations: D-KEFS, Delis-Kaplan Executive Function System; FCSRT, Free and Cued Selective 




Table 6. Sleep measures of CBT-i and Waitlist group at baseline and immediately after weaning, accounting for differences in age, sex and education levels. 
Parameters 
CBT-i 
(PSG n=12; SD n=12 ; Acti 
n=7) 
Waitlist 
















Sleep Diary         
     Sleep Latency (min) 42.51±34.67 32.41±31.77 45.69±37.51 65.31±48.36 0.52 0.472 7.19 0.007* 
     Wake After Sleep Onset (min) 44.48±43.97 21.39±15.76 58.06±43.90 73.34±41.71 1.14 0.285 8.32 0.004* 
     Sleep Efficiency (%) 72.39±25.01 81.17±26.26 79.20±11.59 71.11±13.78 0.04 0.839 16.78 0.000* 









0.98 0.322 6.94 0.008* 
Pittsburgh Sleep Quality Index  11.33±4.31 8.17±4.26 11.33±3.34 10.92±2.87 9.47 0.002* 5.98 0.014* 
Insomnia Severity Index  12.25±5.46 6.92±6.01 16.83±4.55 13.08±6.39 18.08 0.000* 2.72 0.099 
Epworth Sleepiness Scale  4.75±2.70 5.00±4.09 4.92±2.68 4.42±3.09 0.06 0.809 0.48 0.489 
Geriatric Anxiety Inventory  5.33±5.23 4.75±4.81 7.00±5.64 6.25±6.51 0.89 0.345 0.00 0.991 
Geriatric Depression Scale  11.25±2.26 11.42±3.15 13.08±4.29 12.00±3.28 1.56 0.212 3.10 0.078 
Polysomnography Measures          
     Sleep Latency (min)  21.32±25.73 17.12±20.04 18.33±16.37 29.61±38.58 0.20 0.653 1.59 0.207 






4.39 0.036* 0.35 0.552 
     Sleep Efficiency (%) 76.82±10.58 75.40±14.25 76.93±9.64 70.05±11.78 2.54 0.111 1.15 0.283 
     Sustained Sleep Efficiency (%) 80.03±10.64 77.73±13.59 79.95±8.10 73.74±11.84 2.96 0.086 0.67 0.413 









0.52 0.470 0.74 0.388 
     N1 Duration (min) 39.13±27.87 31.08±17.21 46.49±18.35 42.17±22.01 1.48 0.223 0.12 0.729 
     N1 % of TST (%) 11.16±7.84 8.94±4.60 12.18±4.73 12.59±6.43 1.38 0.240 0.11 0.735 









3.13 0.077 0.70 0.402 
     N2 % of TST (%) 59.91±6.02 56.53±11.43 58.76±11.62 57.58±8.63 1.79 0.181 0.00 0.952 
     N3 Duration (min) 47.08±32.25 71.58±40.14 43.23±34.59 50.16±39.44 3.45 0.063 1.19 0.275 
     N3 % of TST (%) 13.38±9.01 19.77±10.53 10.44±7.66 13.12±9.70 4.12 0.042* 0.28 0.596 
     REM Duration (min) 57.45±23.73 54.31±24.82 59.38±36.00 58.65±20.31 3.55 0.160 1.51 0.220 
     REM % of TST (%) 15.55±4.55 14.77±4.86 14.43±8.36 16.69±4.71 0.14 0.706 0.82 0.364 




     Sleep Latency (min) 32.11±17.08 25.62±20.52 52.15±39.97 49.72±18.58 0.72 0.396 1.34 0.247 
     Wake After Sleep Onset (min) 39.03±14.47 30.54±12.51 50.31±24.85 74.92±52.92 0.99 0.320 7.03 0.008* 
     Sleep Efficiency (min) 83.21±3.67 87.83±5.63 79.98±8.61 74.65±4.51 0.00 0.970 13.72 0.000* 









0.01 0.939 0.41 0.520 
Means ± standard deviations are presented and statistically compared using Generalized Estimating Equations. * denotes statistical 
significance at p<0.05. Primary outcome parameters are bolded. 

























Mini-Mental State Exam (score) 28.33±1.78 28.50±2.20 28.25±2.67 28.00±2.17 0.01 0.925 0.21 0.645 
D-KEFS Color Word Interference Test – Color (sec) 32.83±6.48 31.75±6.25 29.50±7.56 30.17±8.74 0.07 0.785 1.86 0.173 
D-KEFS Color Word Interference Test – Color (score) 10.25±2.30 10.50±2.39 11.42±3.06 11.17±3.66 0.00 0.969 0.87 0.351 
D-KEFS Color Word Interference Test – Reading (sec) 24.25±3.84 23.58±4.56 20.75±4.35 22.42±5.05 2.27 0.132 12.38 0.000* 
D-KEFS Color Word Interference Test – Reading 
(score) 
10.42±2.02 10.75±2.42 12.08±2.23 11.33±2.42 0.87 0.350 7.53 0.006* 
D-KEFS Color Word Interference Test – Inhibition (sec) 69.55±18.32 69.67±25.50 63.17±18.81 58.83±15.86 1.24 0.266 1.16 0.282 
D-KEFS Color Word Interference Test – Inhibition 
(score) 
11.00±2.66 10.67±2.81 11.42±2.50 12.17±2.17 0.11 0.737 0.93 0.335 
D-KEFS Color Word Interference Test – Flexibility (sec) 71.50±17.67 68.67±20.88 64.25±16.38 62.25±8.95 1.15 0.284 0.02 0.896 
D-KEFS Color Word Interference Test – Flexibility 
(score) 
11.08±2.27 11.50±2.65 12.25±1.60 12.33±1.23 0.80 0.372 0.38 0.538 
D-KEFS Color Word Interference Test – Total Number 
of Errors 
2.75±2.34 1.67±2.53 2.58±3.09 3.08±2.07 0.61 0.436 0.44 0.506 
Trail Making Test – Part A (sec) 42.33±12.71 41.75±12.26 41.33±11.11 39.08±11.52 0.52 0.472 0.19 0.665 
Trail Making Test – Part A (z-score) 0.43±0.90 0.36±0.87 0.86±1.66 0.44±1.11 0.93 0.336 0.48 0.488 






93.83±43.99 2.03 0.155 0.00 0.982 
Trail Making Test – Part B (z-score) 1.20±3.12 0.50±1.07 0.83±1.56 1.01±1.76 0.28 0.597 0.77 0.381 
Digit Symbol Substitution Test (score) 42.50±9.12 42.83±9.40 45.92±10.77 48.00±9.99 0.89 0.346 0.44 0.509 
FCSRT – Free Recall (score) 30.33±6.30 31.08±6.43 31.17±4.49 32.00±5.74 0.92 0.337 0.00 0.970 
FCSRT – Total Recall (score) 45.75±2.60 44.92±3.96 45.75±2.83 45.42±3.53 0.75 0.386 0.14 0.709 
FCSRT – Cue Efficiency (%) 88.89±12.27 85.48±14.77 90.92±13.10 86.18±16.84 2.20 0.138 0.05 0.818 
FCSRT – Delayed Free Recall (score) 11.92±2.15 12.08±2.64 12.50±2.68 13.08±1.93 0.63 0.427 0.18 0.672 
FCSRT – Delayed Total Recall (score) 15.75±0.45 14.00±4.22 15.83±0.39 14.67±4.31 2.72 0.099 0.12 0.726 
FCSRT – Delayed Recall Cue Efficiency (%) 96.38±6.62 84.46±18.67 97.69±5.19 94.32±15.17 4.63 0.032* 1.83 0.177 









0.03 0.852 0.47 0.494 




MTCF/ROCF – Copy (z-score corrected for SES) 0.15±0.57 0.22±0.78 -0.01±0.81 0.76±0.56 6.17 0.013* 4.33 0.037* 
MTCF/ROCF – Copy (z-score corrected for All 
variables) 
0.06±0.57 0.14±0.77 -0.12±0.84 0.66±0.58 6.59 0.010* 4.35 0.037* 
MTCF/ROCF – Immediate Recall (score) 15.21±4.83 17.67±3.23 17.54±5.24 17.29±6.51 1.35 0.245 1.98 0.159 
MTCF/ROCF – Immediate Recall  (z-score corrected 
for SES) 
-0.10±0.90 0.33±0.65 0.35±0.95 0.31±1.15 1.28 0.257 1.81 0.178 
MTCF/ROCF – Immediate Recall  (z-score corrected 
for All variables) 
-0.55±0.90 -0.03±0.98 0.07±1.06 -0.54±1.31 0.03 0.868 4.21 0.040* 
Purdue Pegboard Dominant Hand (Score) 12.00±1.81 12.08±2.07 13.33±1.44 13.75±1.86 0.76 0.383 0.31 0.581 
Purdue Pegboard Dominant Hand (z-score) -0.35±1.21 -0.28±1.30 0.04±0.93 0.30±1.09 0.56 0.456 0.19 0.664 
Purdue Pegboard – Non-Dominant Hand (Score) 12.00±1.41 12.33±1.30 12.50±1.31 12.17±2.82 0.00 0.996 0.59 0.442 
Purdue Pegboard – Non-Dominant Hand (z-score) -0.16±0.88 0.28±1.01 -0.13±0.51 0.24±0.84 5.15 0.023* 0.04 0.841 
Purdue Pegboard – Both Hands (score) 9.92±1.68 9.67±2.06 10.08±1.31 10.75±1.71 0.59 0.443 3.19 0.074 
Purdue Pegboard – Both Hands (z-score) 0.19±1.46 0.15±1.62 0.30±1.48 0.66±1.45 0.26 0.608 0.43 0.514 
Means ± standard deviations are presented and statistically compared using Generalized Estimating Equations. * denotes statistical 
significance at p<0.05.  
Abbreviations: D-KEFS, Delis-Kaplan Executive Function System; FCSRT, Free and Cued Selective Reminding Test; MTCF, Modified Taylor 





Table 8. Cognitive measures of Pooled CBT-i group (CBT-i and Waitlist who completed CBT-i post weaning) at baseline and immediately after 







 Pre CBT-i Post CBT-i Wald χ2 p value 
Mini-Mental State Exam (score) 28.44±1.71 28.56±1.80 0.11 0.05 0.816 
D-KEFS Color Word Interference Test – Color (sec) 30.94±6.25 28.94±7.48 -2.00 2.65 0.103 
D-KEFS Color Word Interference Test – Color (score) 10.94±2.30 11.22±2.44 0.28 1.17 0.279 
D-KEFS Color Word Interference Test – Reading (sec) 22.61±4.18 21.33±5.35 -1.28 2.37 0.123 
D-KEFS Color Word Interference Test – Reading (score) 11.17±2.14 11.33±2.33 0.17 0.44 0.505 
D-KEFS Color Word Interference Test – Inhibition (sec) 67.39±16.18 64.17±23.22 -3.22 1.42 0.234 
D-KEFS Color Word Interference Test – Inhibition (score) 11.17±2.46 11.56±2.79 0.39 0.28 0.597 
D-KEFS Color Word Interference Test – Flexibility (sec) 67.39±16.18 64.17±23.22 -3.22 0.845 0.358 
D-KEFS Color Word Interference Test – Flexibility (score) 11.61±2.11 11.72±2.64 0.11 0.09 0.766 
D-KEFS Color Word Interference Test – Total Number of Errors 2.83±2.83 1.67±2.11 -1.17 3.24 0.072 
Trail Making Test – Part A (sec) 42.28±11.79 38.61±11.64 -3.67 2.05 0.153 
Trail Making Test – Part A (z-score) 0.72±1.29 0.25±1.03 -0.48 2.04 0.153 
Trail Making Test – Part B (seconds) 99.00±59.25 94.06±48.00 -4.94 0.46 0.500 
Trail Making Test – Part B (z-score) 0.96±2.48 0.56±1.19 -0.41 0.45 0.504 
Digit Symbol Substitution Test (score) 42.89±8.61 45.78±10.76 2.89 3.52 0.061 
FCSRT – Free Recall (score) 30.56±5.25 32.78±5.87 2.22 4.92 0.027* 
FCSRT – Total Recall (score) 45.56±2.73 45.61±3.30 0.06 0.00 0.947 
FCSRT – Cue Efficiency (%) 87.81±12.96 87.62±12.53 -0.19 0.00 0.957 
FCSRT – Delayed Free Recall (score) 12.17±2.14 12.44±2.24 0.28 0.29 0.593 
FCSRT – Delayed Total Recall (score) 15.78±0.42 14.61±3.42 -1.17 1.89 0.169 
FCSRT – Delayed Recall Cue Efficiency (%) 96.79±6.05 88.21±17.66 -8.58 4.25 0.039* 
MTCF/ROCF – Copy (sec) 165.22±43.01 161.67±55.75 -3.56 0.07 0.795 
MTCF/ROCF – Copy (score) 31.94±1.99 32.06±2.72 0.11 0.03 0.862 
MTCF/ROCF – Copy (z-score corrected for SES) 0.14±0.59 0.17±0.71 0.03 0.04 0.848 
MTCF/ROCF – Copy (z-score corrected for All variables) 0.05±0.61 0.08±0.71 0.03 0.02 0.876 
MTCF/ROCF – Immediate Recall (score) 16.08±5.43 17.78±4.40 1.69 2.93 0.087 
MTCF/ROCF – Immediate Recall  (z-score corrected for SES) 0.05±0.98 0.36±0.83 0.30 3.26 0.071 
MTCF/ROCF – Immediate Recall  (z-score corrected for All variables) -0.35±1.00 -0.01±0.95 0.34 1.43 0.232 
Purdue Pegboard Dominant Hand (Score) 12.33±1.67 12.72±1.91 0.39 1.90 0.169 




Purdue Pegboard – Non-Dominant Hand (Score) 12.22±1.31 12.72±1.41 0.50 3.07 0.080 
Purdue Pegboard – Non-Dominant Hand (z-score) -0.20±0.73 0.22±0.88 0.42 6.17 0.013* 
Purdue Pegboard – Both Hands (score) 10.06±1.39 10.06±1.87 0.00 0.00 1.000 
Purdue Pegboard – Both Hands (z-score) 0.15±1.27 0.20±1.47 0.05 0.02 0.879 
Means ± standard deviations are presented and statistically compared using Generalized Estimating Equations. * denotes statistical significance at p<0.05.  

















Figure 2. Schematic representation of the study procedure, demonstrating recruitment, baseline evaluations, group assignment and intervention received in each 






Figure 3. Changes in the sleep diary sleep latency from pre- to post-intervention. The dots represent the mean value, 
the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. Generalized 
Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. There was no 
effect of weaning alone (p=0.472), but there was a significant time-group interaction (p=0.007).  
 
 
Figure 4. Changes in the sleep diary wake after sleep onset from pre- to post-intervention. The dots represent the 
mean value, the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 







Figure 5. Changes in the sleep diary sleep efficiency from pre- to post-intervention. The dots represent the mean 
value, the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 
There was no effect of weaning alone (p=0.839), but there was a significant time-group interaction (p=0.000). 
 
 
Figure 6. Changes in the sleep diary total sleep time from pre- to post-intervention. The dots represent the mean 
value, the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 






Figure 7. Changes in the Pittsburgh sleep quality index from pre- to post-intervention. The dots represent the mean 
value, the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 
There was a significant effect of weaning alone (p=0.002), and a significant time-group interaction (p=0.014). 
 
 
Figure 8. Changes in the insomnia severity index from pre- to post-intervention. The dots represent the mean value, 
and the bars show the standard error of the mean. Generalized Estimating Equation was used, accounting for age, 
sex, education level with significance set at p<0.05. There was a significant effect of weaning alone (p=0.000), and a 






Figure 9. Changes in Polysomnography wake after sleep onset from pre- to post-intervention. The dots represent the 
mean value, and the bars show the standard error of the mean. Generalized Estimating Equation was used, 
accounting for age, sex, education level with significance set at p<0.05. There was a significant effect of weaning 
alone (p=0.036), but no time-group interaction (p=0.552). 
 
 
Figure 10. Changes in Polysomnography stage N3 NREM sleep duration from pre- to post-intervention. The dots 
represent the mean value, and the bars show the standard error of the mean. Generalized Estimating Equation was 
used, accounting for age, sex, education level with significance set at p<0.05. There was a significant effect of 






Figure 11. Changes in actigraphy wake after sleep onset from pre- to post-intervention. The dots represent the mean 
value, the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 
There was no effect of weaning alone (p=0.320), but there was a significant time-group interaction (p=0.008). 
 
 
Figure 12. Changes in actigraphy sleep efficiency from pre- to post-intervention. The dots represent the mean value, 
the bars show the standard error of the mean, and the asterisk denote significant group-time interaction. Generalized 
Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. There was no 





Figure 13. Changes in reading component of Delis–Kaplan executive function system (measured in seconds) from 
pre- to post-intervention. The dots represent the mean value, the bars show the standard error of the mean, and the 
asterisk denote significant group-time interaction. Generalized Estimating Equation was used, accounting for age, 
sex, education level with significance set at p<0.05. There was no effect of weaning alone (p=0.132), but there was a 




Figure 14. Changes in reading component of Delis–Kaplan executive function system (scaled score, accounting for 
age) from pre- to post-intervention. The dots represent the mean value, the bars show the standard error of the 
mean, and the asterisk denote significant group-time interaction. Generalized Estimating Equation was used, 
accounting for age, sex, education level with significance set at p<0.05. There was no effect of weaning alone 





Figure 15. Changes in delayed recall cue efficiency component of the free and cued selective reminding test from 
pre- to post-intervention. The dots represent the mean value, and the bars show the standard error of the mean. 
Generalized Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. 




Figure 16. Changes in the copy component of the modified Taylor/Rey Osterrieth complex figure (score) from pre- to 
post-intervention. The dots represent the mean value, the bars show the standard error of the mean, and the asterisk 
denote significant group-time interaction. Generalized Estimating Equation was used, accounting for age, sex, 
education level with significance set at p<0.05. There was a significant effect of weaning alone (p=0.014), and a 






Figure 17. Changes in the copy component of the modified Taylor/Rey Osterrieth complex figure (SES Z-score) from 
pre- to post-intervention. The dots represent the mean value, the bars show the standard error of the mean, and the 
asterisk denote significant group-time interaction. Generalized Estimating Equation was used, accounting for age, 
sex, education level with significance set at p<0.05. There was a significant effect of weaning alone (p=0.013), and a 
significant time-group interaction (p=0.037). 
 
 
Figure 18. Changes in the copy component of the modified Taylor/Rey Osterrieth complex figure (all variable Z-score) 
from pre- to post-intervention. The dots represent the mean value, the bars show the standard error of the mean, and 
the asterisk denote significant group-time interaction. Generalized Estimating Equation was used, accounting for age, 
sex, education level with significance set at p<0.05. There was a significant effect of weaning alone (p=0.010), and a 






Figure 19. Changes in the recall component of the modified Taylor/Rey Osterrieth complex figure (all variable Z-
score) from pre- to post-intervention. The dots represent the mean value, the bars show the standard error of the 
mean, and the asterisk denote significant group-time interaction. Generalized Estimating Equation was used, 
accounting for age, sex, education level with significance set at p<0.05. There was no effect of weaning alone 
(p=0.868), but there was a significant time-group interaction (p=0.040). 
 
 
Figure 20. Changes in non-dominant hand component of Purdue pegboard test (z-score) from pre- to post-
intervention. The dots represent the mean value, and the bars show the standard error of the mean. Generalized 
Estimating Equation was used, accounting for age, sex, education level with significance set at p<0.05. There was a 
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